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Abbreviations:  
2-DE,  2-dimensional electrophoresis 
ACPA,  anti-citrullinated protein/peptide antibodies  
BMP,   bone morphogenetic protein 
CAM,  cell associated matrix 
CID,  collision-induced dissociation 
CRP,   C-reactive protein 
DMEM, Dulbecco’s modified Eagle medium 
DIGE,  difference gel electrophoresis 
ECL,  enhanced chemiluminescence 
ECM,   extracellular matrix  
ESI,  electrospray ionization 
FLS,   fibroblast-like synoviocytes 
FPA,  forward-phase protein microarray 
HBSS,  Hank’s balanced salt solution  
HRP,  horseradish peroxidase 
IEF,  iso-electric focusing 
IF,  immunofluorescence 
IGF-1,  insulin-like growth factor 1  
IL-1,   interleukin-1 
IPG,  immobilized pH gradients 
LC,  liquid chromatography 
MALDI, matrix-assisted laser desorption/ionization 
MLS,   macrophage-like synoviocytes 
MRM,  multiple reaction monitoring  
Mw,  molecular weight 
MS,  mass spectrometry 
NGS,   normal goat serum  
OA,   osteoarthritis 
PAGE, poly-acrylamide gel electrophoresis 
PBS,  phosphate-buffered saline 
pI,  isoelectric point 
PTM,  post-translational modification 
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RA,  rheumatoid arthritis 
RNAi,  RNA interference  
ROS,   reactive oxygen species  
RPA,  reverse-phase protein microarray 
RT-PCR, reverse-transcriptase polymerase chain reaction 
SELDI, surface-enhanced laser desorption/ionization 
sHSP,   small heat-shock protein 
siRNA,  short interfering RNA 
SJIA,   systemic juvenile idiopathic arthritis  
SLE,   systemic lupus erythematosus 
SpA,   spondylarthropathies 
TGF-β,  transforming growth factor β  
TMA,  tissue microarray 
TNF-α,  tumor necrosis factor α 
TOF,  time-of-flight 
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 Abstract 
One of the major challenges in proteome research is to translate its applications to the setting 
of human diseases. Proteomics in rheumatology is an area with marked potential including 
applications ranging from diagnostics, over therapeutic monitoring to discovery of new 
potential therapeutic targets.  
Biomarkers will be essential to discriminate between clinical similar rheumatic diseases, to 
monitor disease-states or to install the best appropriate therapy. Especially in the field of 
rheumatology, analysis of specific genes and/or their expression products by 
pharmacogenetics/-genomics or pharmacoproteomics could be necessary to enable an 
effective, patient-tailored therapy. 
In rheumatology, direct examination of proteins may be of the utmost importance, as it is 
already known that post-translational modifications, such as citrullination of proteins or 
peptides, may be involved in certain rheumatic diseases. The discovery and validation of anti-
citrullinated protein/peptide antibodies and other auto-antibodies in rheumatic diseases using 
proteome analysis approaches has been described. 
Gel-free methods, SELDI-approaches and classic 2-DE approaches have been deployed on 
body fluids as well as on target tissues in different rheumatic diseases. Proteomics in 
rheumatology is on the rise and pilot studies have indicated that the application of proteomics 
based technologies in rheumatic diseases appears to be an exciting example of translational 
research.  
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 1. Introduction 
Rheumatology is a discipline of internal medicine which diagnoses and manages a series of 
related diseases. The primarily targeted organs are the joints. It is therefore obvious that, in 
addition to serum, the joint tissues are the most frequently investigated by proteomics in 
rheumatology research, although other organs such as kidneys, lungs and skin may also be 
affected.  
 
1.1 Joint anatomy 
A joint is an organ where two or more bones are “connected” with each other. Joints can be 
classified based on histological features. Three types of joints are generally discriminated: the 
fibrous joints, cartilaginous joints and synovial joints. The synovial joints (or diarthroidal 
joints) are the joints affected by arthritis, the most common symptom in rheumatology. 
Synovial joints are surrounded by a capsule that defines the boundary between articular and 
peri-articular tissues [1] (figure 1). The stability of the joint is provided by the bones, 
ligaments, joint capsule and the muscles. The articulating bone surfaces have at their ends a 
thin plate of dense bone; the articular endplate [2]. Adherent to the bony endplate is the 
hyaline articular cartilage; a specialized smooth connective tissue that is both weight bearing 
and serves as a gliding surface allowing a lithe movement of the joints. The articular cartilage 
consists of an extracellular matrix (ECM), which contains and is formed by the only resident 
cells, the chondrocytes. This tissue is extremely well adapted to bear loads associated with 
joint use.  The articular cartilage is in contact with the joint cavity, which is filled with an 
aqueous solution of hyaluronan. Together with the vasculature of the subchondral bone, this 
fluid serves as a nutrient source for the avascular, aneural and alymphatic articular cartilage. 
In inflammatory conditions, this synovial fluid is actually an ultrafiltrate of plasma with the 
addition of locally produced hyaluronan, and it is characterized by an accumulation of 
inflammatory cells such as macrophages, B lymphocytes and T lymphocytes. The amount of 
synovial fluid in the joint cavity and its content is regulated by the synovial membrane; a 
vascular connective tissue lining the inner surface of the joint capsule [2]. The synovium 
consists of two layers: the synovial lining (surface layer) and sublining (the underlining layer) 
and two distinct synoviocytes can be distinguished: macrophage-like and fibroblast-like 
synoviocytes [3]. All of the above mentioned structures may be affected during the 
development of the different forms of arthritis.   
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Figure 1: Schematic representation of a synovial joint, indicating the different bone matrices and the primary 
targeted articular structures in rheumatic diseases.  
 
 
1.2 The rheumatic diseases 
As stated above, rheumatology consists of a complex group of related diseases with very 
heterogeneous clinical appearance and which may occur at any age. Rheumatoid arthritis 
(RA) and osteoarthritis (OA) are the most frequently occurring and investigated rheumatic 
diseases.  
RA is generally considered as a chronic, inflammatory, autoimmune disorder (for a review see 
[4] and [5]). It mainly affects the smaller joints in a symmetric way. It is characterized by an 
inflammation of multiple joints, which ultimately results in the erosion and destruction of 
joint structures due to the invasion of activated synoviocytes and osteoclast activation. While 
the primary target of RA is the synovial membrane, advanced RA, however, is accompanied 
by a progressive destruction of other joint structures such as the articular cartilage and 
subchondral and periarticular bone [6]. Besides the joint involvement, extra-articular features 
including vasculitis and subcutaneous nodules may also occur. 
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 Besides RA, a group of other inflammatory joint diseases can be distinguished; the 
spondylarthropathies (SpA). Clinical symptoms of SpA comprise of inflammatory back pain, 
asymmetrical oligoarthritis and inflammation of other organs such as the gut, the skin or the 
eye. Five different subgroups can be discriminated: ankylosing spondylitis, psoriatic 
spondyloarthritis, reactive spondyloarthritis, spondyloarthritis associated with inflammatory 
bowel disease and undifferentiated spondyloarthritis [7]. Hallmarks of these types of chronic 
arthritis are that the destructive properties are simultaneously combined with the formation of 
new bone. Some groups have therefore termed these types of disorders as an example of 
destructive and remodelling arthritis. 
Juvenile idiopathic arthritis encompasses all forms of arthritis that begin before the age of 16 
years, persist for more than 6 weeks, and are of unknown cause. It is a general term that 
describes a clinically heterogeneous group of arthritides (reviewed in [8]).  Interestingly, 
symptoms of these different forms of arthritis are not limited to the joints, but may include 
systemic symptoms such as fever, lymphadenopathy and hepatosplenomegaly. 
Two rheumatic diseases which do not primarily target the joints are systemic lupus 
erythematosus (SLE) and Sjögren’s syndrome. SLE is a systemic auto-immune disease of 
unknown aetiology. Symptoms are rather heterogeneous and the targeted organs include the 
skin, kidneys, muscles, lungs and the heart. Psychological symptoms such as anxiety, 
depression and fatigue are commonly observed. Sjögren’s syndrome is also a systemic auto-
immune disease, which primarily targets the exocrine glands resulting in dryness of the eyes 
and mouth. However, as in SLE internal organs may also be affected by this disease. 
Furthermore, other systemic diseases such as systemic sclerosis are also followed by 
rheumatologists. 
In contrast to inflammatory arthritides, OA is not considered a classical inflammatory 
arthropathy, due to the absence of inflammatory cells in the synovial fluid and the lack of 
systemic signs of inflammation. However, some studies suggested that some signs of synovial 
inflammation may occur during the course of the disease [9]. It is a slowly progressive disease 
characterized by a degeneration of the articular cartilage, which mostly affects the large 
weight-baring joints (for an extended review see [10]). The cartilage degeneration is the 
ultimate result of an imbalance between anabolic and catabolic processes in the chondrocyte. 
Cartilage deterioration combined with other structural changes (e.g. formation of new bone at 
the joint margins) leads to malalignment of the joint, which ultimately results in joint failure. 
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 1.3 The need for translational research in rheumatology 
Proteome studies in rheumatology mainly focus on two different domains: biomarker 
discovery and the search for new key players in disease pathogenesis. A biomarker has been 
defined by the Biomarkers Definition Working Group as: “A characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic processes 
or pharmacological responses to a therapeutic intervention” [11]. This definition implies that 
biomarkers may not only be used to stratify patients or to predict outcome, but also to predict 
responders and non-responders to a given therapy.  
Probably, the area with greatest potential in rheumatology research is biomarker discovery. It 
is of utmost importance for a rheumatologist to be able to discriminate and to recognize 
different disease subtypes. Nowadays, diagnosis is largely based on clinical observations 
combined with serological analyses and synovial histological features. However, clinical 
symptoms may develop initially rather atypical and the course of the disease may be very 
unpredictable. Today, the major challenge remains to predict disease development or 
evolution, even before the presentation of major clinical symptoms. Particularly in the case of 
RA, it is known that in the initial phase of the disease, the rate of joint destruction is very high 
[12].  Synovial activation may occur before the development of clinical symptoms or even 
persist despite remission of clinical signs, reflecting the need for early-disease markers. In the 
case of ankylosing spondylitis, there is an average interval from 8-11 years, between the onset 
of symptoms and the time of diagnosis [13]. The knowledge of early molecular markers could 
help the clinician to shorten this interval and to implement the appropriate therapy. Good 
biomarkers may not only serve as early diagnostic tools, but also as predictors of disease 
progression and therapeutic response. For example, in RA there are very few clear-cut 
differences between early and late stages of RA and even on the histological level, RA cannot  
invariably be distinguished from other types of synovitis [3].  
A major criterion for a good biomarker is its presence in an easily accessible body fluid. In 
joint pathologies, synovial fluid serves as an additional body fluid for biomarker-screening. In 
inflammatory conditions, the synovial fluid is actually an ultrafiltrate of plasma with the 
addition of locally produced hyaluronan, and it is characterized by an accumulation of 
inflammatory cells such as macrophages, B lymphocytes and T lymphocytes. As synovial 
activation is one of the primary manifestations in inflammatory pathologies, such as RA, the 
synovial fluid is very commonly screened in biomarker discovery studies. As described in the 
introduction, most rheumatic diseases are characterized as auto-immune diseases. This opens 
the perspective to use auto-antibodies as potential biomarkers, as will be discussed later.  
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 A second area of translational research in rheumatology is the search for key players in 
disease pathogenesis. The knowledge of differentially abundant proteins in a target tissue may 
provide new insights in the pathogenesis, which may open avenues for the rational 
development of new targeted therapies. For example, in OA no sufficiently satisfactory 
disease-modifying drugs are available and therefore, drug therapy is mainly limited to the 
control of symptoms [14]. Thus, the knowledge of the underlying disease processes may be of 
invaluable significance. In inflammatory pathologies, underlying disease mechanisms can be 
elucidated by analyzing the synovial membrane which is believed to be one of the initial sites 
where the disease occurs and progresses. Alternatively, exposing cultured synoviocytes to 
various inflammatory conditions can provide insight in the inflammatory pathways triggered 
in the joint. In OA, generally considered as a non-inflammatory disease, the chondrocytes 
play a pivotal role in the slowly progressive degeneration of the articular cartilage [15]. As a 
consequence, isolated chondrocytes and the articular cartilage itself are very attractive 
subjects to study OA pathogenesis.  
 
The results of studying target tissues or body fluids by the use of proteomics techniques are 
intertwined: analysis of serum or synovial fluid may lead to the discovery of new rheumatic 
biomarkers but can also provide new insights into the pathogenesis and the knowledge of the 
disease. In contrast, studying target tissues and the subsequent discovery of disease pathways, 
may lead to rational biomarker discovery. 
 
2. What did proteomics learn us about rheumatology? 
2.1 Serological markers and auto-antigen discovery 
The majority of rheumatic diseases are known as auto-immune diseases. A lot of efforts have 
been made to characterize auto-antibodies and the antigens they are directed against. Besides 
a diagnostic value, their identification may provide new insights into the pathogenesis of 
rheumatic diseases and auto-immune diseases in general.  
The most common serological marker for RA is the presence of rheumatoid factor. This factor 
is an immunoglobulin (Ig) M antibody response directed against the Fc portion of IgG, 
leading to the formation of complexes [16]. However, this antibody is not very specific for 
RA (specificity: 74%, sensitivity: 75% [17]) and can be found in many other inflammatory 
diseases and in healthy elderly individuals [18]. In recent years, a variety of additional auto-
antibodies have been described in patients with RA (reviewed in [19]). Antibodies against 
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 citrulline containing proteins (ACPA) have shown to be highly specific for RA (specificity: 
96-98 % [20, 21]), without compromising their sensitivity. They can be observed in the serum 
of patients before clinical onset [22, 23]. During citrullination, arginine residues are post-
translationally, enzymatically converted into citrulline residues (figure 2). A detailed reaction 
mechanism for this enzymatic conversion was proposed by Arita et al [24]. The reaction is 
catalyzed by the enzyme peptidylarginine deiminase (PAD). The arginine residue is targeted 
via a cysteine residue of the enzyme, yielding a tetrahedral adduct. Nucleophilic attack by 
water results in the formation of ammonia and the citrulline residue, which differs 1 Da in 
mass from the original arginine (figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Illustration of the reaction mechanism, describing the enzymatic conversion of an arginine residue into 
citrulline. The reaction is catalyzed by the enzyme peptidylarginine deiminase (PAD). This enzyme targets the 
arginine residue via a cysteine residue, yielding a tetrahedral adduct. A nucleophilic attack of water results in the 
formation of the keto-group and release of the cysteine residue. The resulting citrulline residue differs 1 Da in 
mass from the original arginine. 
 
Besides the autoantibody response, there is some indirect evidence suggesting a more 
important role for protein citrullination in the pathogenesis of RA since ACPA can be 
observed in the sera of patients before clinical onset [22, 23]. Anti-CCP (anti-cyclic 
citrullinated peptides) producing plasma cells have been shown in the inflamed synovial RA 
tissue [25] suggesting the presence of citrullinated proteins in the synovial membrane causing 
an antigen driven maturation of ACPA-specific B cells at the site of inflammation. Indeed, the 
presence of citrullinated proteins, like fibrinogen α and fibrinogen β, have been shown in the 
RA synovium [26]. However, these forms of fibrin are not specific for RA but are also 
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 observed in non-RA synovium [27]. The presence of ACPA is also strongly associated with a 
specific Major Histocompatibility Complex background: HLA-DR shared epitope positive 
RA patients have higher ACPA levels [28].  
However, it is still largely unknown, what the exact role is of protein citrullination in arthritis, 
as PAD expression and citrullination of proteins are found in other tissue and pathologies [29, 
30].  This process of arginine transformation could be a more universal characteristic of 
inflammation, although very little is known about the function of protein citrullination in 
general.  
 
Proteomics techniques are very well suited to discover post-translational modification of 
antigens. In the recent years 2-DE has repeatedly been used to elucidate antibody responses 
especially to modified proteins and it still holds great promise in the discovery of new auto-
antigens which is a hot topic in the auto-immune disease research. In general, tissue proteins 
are separated by 2-DE followed by western blotting and incubation with sera of patients.  
For the discovery of new citrullinated synovial auto-antigens, such an approach was applied 
by Matsuo et al [31]. Thirteen citrullinated auto-antigenic protein spots were identified in a 
RA synovial tissue sample. The usefulness of such 2-DE approach was also demonstrated by 
our own group [32]: protein patterns of some immunoreactive spots appeared as “trains” on 
the 2-D gel. Subsequently, these protein modifications were identified as citrullinated subunits 
of   fibrinogen. Other 2-DE based approaches, suggested that auto-antibodies against aldolase 
A [33] and α-enolase [34] are also associated with RA. The authors of the latter study 
suggested that RA sera showed autoreactivity predominantly to a posttranslationally modified 
or appropriately folded epitope of α-enolase. Kinloch et al. confirmed α-enolase as a potential 
auto-antigen in RA, more specifically the citrullinated form of α-enolase [35]. Undoubtedly, 
post-translational modifications can induce a break in tolerance and can initiate the production 
of antibodies. It is not unlikely that in the near future, besides citrullination, other antigen 
modifications will be identified by proteomics techniques which are associated with the 
development of auto-immune diseases. 2-DE approaches should still be considered as a very 
powerful tool in the discovery of new auto-antigens as they can precisely indicate against 
which protein spot the specific auto-antibodies in the sera of patients react.   
An alternative approach, using antigen microarrays, demonstrated that citrullinated epitopes 
were prefentially targeted by auto-antibodies present in serum of patients with features 
predictive of severe arthritis. In contrast, autoreactivity against a set of native auto-antigens 
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 could discriminate a subpopulation of patients with early RA with features predictive of mild 
arthritis [36]. Another microarray analysis by the same group showed clear association 
between anti-citrulline reactivity and elevated blood levels of pro-inflammatory cytokines in 
patients with early RA [37]. Feng et al. used arrays loaded with 15 known auto-antigens in 
rheumatic diseases and incubated them with serum samples from patients with different 
autoimmune rheumatic diseases. Given the reported correlation of specificity and sensitivity 
with previously reported data, the authors present such arrays as a potential high-throughput 
diagnostic tool, which allows parallel screening of different auto-antigens [38]. 
Whereas autoimmune processes are well described in RA, OA is generally considered as a 
non-inflammatory, degenerative disease. However, it has been suggested that autoimmune 
processes directed against cartilage components might play a role in the cartilage destruction 
associated with OA [39]. Fibulin-4, a cartilage matrix protein, has been identified as a 
potential auto-antigen in OA and might play a role in OA pathogenesis [40]. The same group 
described triosephosphate isomerase as an auto-antigen in OA as revealed by a proteomics 
study [41]. 
In addition to RA and OA, proteomics-based auto-antibodies discovery studies have also been 
deployed to investigate lupus disease activity. Glomerular proteome arrays, containing about 
30 antigens documented to be present in the glomerular milieu, unravelled several IgG and 
IgM auto-antibody clusters. Two of the IgG antibody clusters were found to correlate well 
with disease severity, whereas one IgM cluster was associated with reduced disease severity 
[42]. One of the major disadvantages of such antigen-arrays, is the difficulty to unravel novel 
auto-antigens, as they contain only a limited number of presented antigens. 
 
Especially in the field of the inflammatory diseases, auto-antibody discovery is of the utmost 
importance, not only as a diagnostic marker, but also to provide new insights in the 
pathogenesis of different related diseases. Pilot proteomics-based studies have confirmed 
known phenomena and provided novel potential interesting targets. Probably, the greatest 
potential of such studies lies in the ability to detect different isoforms of a single protein, as it 
has become clear that post-translational modifications have a great impact on the development 
of auto-antibodies.  
 
2.2 The search for biomarkers in serum/plasma or synovial fluid 
Several groups have analysed synovial fluid, serum or plasma samples using 2-DE in order to 
find biomarkers which can distinguish RA from other joint diseases [43, 44]. Based on a 
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 differential proteome study, the authors of the latter study validated the applicability of the 
S100A8/S100A9 heterocomplex as a diagnostic marker for RA using ELISA. The S100A9 
protein was also identified in the former study as differentially expressed in RA synovial fluid 
compared to OA. In addition, the authors reported the selective presence of serum amyloid A 
in RA synovial fluid and plasma. A single biomarker, which distinguishes RA from all other 
diseases, is probably unrealistic. It is more likely that a combination of proteins will be more 
conclusive. Dotzlaw et al [45] used a subset of 29 differentially expressed proteins in 
peripheral blood mononuclear cells for a hierarchical cluster analysis, enabling total 
segregation of patients and controls.  
As stated before, a set of biomarkers, disclosed by proteome analysis, is not only useful for 
patient stratification but also to monitor therapy response. Smith et al [46] were the first to 
demonstrate this principle in the field of rheumatology: levels of acute-phase proteins in 
synovial fluid, quantified after 2-DE separation, correlated well with clinical conditions and 
other parameters of disease progression after anti-CD4 administration.  
Synovial fluids of OA patients have also been screened by 2-DE, however no comparison was 
made with other diseases [47]. An exploratory study investigated synovial proteomes of 
children with single and recurrent joint inflammation and compared these patterns with 
corresponding plasma samples, in an attempt to identify proteins which were over-expressed 
in the joints or in recurrent inflammation [48].  
In recent years, a lot of effort has been made to omit the labour-intensive 2-DE gels. Also in 
the field of rheumatology, gel-free methods have been applied in the search for suitable 
biomarkers. A SELDI TOF-MS analysis compared synovial fluids of RA and OA patients, 
revealing several biomarker candidates for RA [49]. After further purification, identification 
and validation experiments the authors proposed the S100A8 protein as a candidate 
biomarker. These S100 proteins have been associated with several other inflammatory 
diseases and it is now generally accepted that these proteins may have proinflammatory 
functions in several autoinflammatory disorders [50]. Not surprisingly, these S100 proteins 
have been identified in several rheumatic biomarker screening studies as differentially 
expressed proteins. Altogether, these proteins should be considered as markers of the 
inflammatory disease state, rather than specific RA-biomarkers. One of the major 
disadvantages of a SELDI platform is that it does not allow direct identification of the 
potential interesting spectrum peaks. In experimental settings, a cluster of unidentified peaks 
may be used to discriminate RA-patients from controls [51] or active versus inactive lupus 
disease states [52]. Miyamae et al [53] performed a SELDI analysis on serum samples of 
21
 systemic juvenile idiopathic arthritis (SJIA) patients, demonstrating the potential of such an 
approach to discriminate between different disease states based on a set of peaks. One of these 
peaks was subsequently identified as serum amyloid A, a known acute-phase reactant in SJIA. 
In addition, the authors presented a set of unidentified peaks predictive for therapy response. 
While these studies are very promising in experimental settings, it has to be kept in mind that 
it is very unlikely that diagnostic tests will be used in clinical practice without the knowledge 
of biomarker identity. Therefore, these studies should be regarded as proof-of-principle rather 
than an endpoint. 
SELDI approaches have also been used in the search for biomarkers in Sjögren’s syndrome. 
SELDI combined with a 2-D differential gel electrophoresis (2-D DIGE) was applied to 
compare saliva samples from Sjögren’s Syndrome-patients with healthy subjects. This 
revealed a set of previously described and novel potential biomarkers, of which lactoferrin 
and β2-microglobulin have been validated by ELISA [54]. Tear proteomic patterns in 
Sjögren’s Syndrome have been investigated by SELDI TOF-MS, yielding a set of protein 
peaks with potential predictive value for Sjögren’s Syndrome diagnosis [55].  
NanoLC-MS/MS methods were introduced in rheumatology biomarker research by Kuhn et al 
[56]. They demonstrated the ability of a nanoLC-MS/MS platform, based on multiple-reaction 
monitoring (MRM), to quantitate C-reactive protein (CRP), a known diagnostic marker for 
RA, in serum samples. In a later study [57], the same group combined this MRM approach to 
validate candidate markers, selected by a differential 2-D nanoLC-MS/MS screening analysis. 
Among these candidates were proteins known to be associated with inflammatory processes, 
such as S100 proteins and CRP, demonstrating the potential as a discovery tool.   
 
2.3 The search for mechanisms involved in pathogenesis: proteome analyses of target 
tissues 
In inflammatory pathologies, disease modifying drug therapies have been developed in the 
recent years, although the disease mechanisms are not yet fully understood. On the other 
hand, drug treatment for OA, the most common form of joint diseases, is limited to symptom 
control management without convincing effects on disease progression [58]. Differential 
proteome analyses comparing different disease states or diseased versus healthy samples 
might help us to provide new insights in the pathogenesis of rheumatic diseases. In addition, 
well defined animal models (e.g. rats with surgically induced OA by anterior cruciate 
ligament transaction) may also assist in the discovery of novel disease pathways. Such 
approach was recently demonstrated at the RNA level to identify genes involved in OA 
22
 pathogenesis [59]. Moreover, given the continuous growth in commercially available knock-
out animals, such models may serve as an excellent tool to validate proteome analysis data. 
Well validated proteome generated data, may ultimately help to unravel disease pathways and 
assist in drug development. Given the heterogeneity in progression or therapeutic response, 
the knowledge of detailed rheumatic disease mechanisms undoubtedly will assist in novel 
therapy developments.   
 
2.3.1 Synovial tissue 
Synovial tissue is characterized by the presence of two different cell types: fibroblast-like 
(FLS) and macrophage-like synoviocytes (MLS) [60].  The synovium is the primarily targeted 
tissue during inflammatory joint pathologies. In conditions such as RA or SpA the 
physiological synovium alters into an inflammatory activated synovium [3]. The proteome of 
cultured FLS derived from RA-synovium was characterized using a 2-DE approach followed 
by mass spectrometry [61]. However, the authors did not compare the protein expression 
pattern between different diseases. Our own group compared the expression levels by 2-DE of 
soluble proteins extracted from RA, SpA and OA synovia [62]. Based on a hierarchical 
cluster analysis, it was concluded that RA and SpA patients showed a distinguished 
expression pattern, even though both are inflammatory pathologies. Not surprisingly, the 
previously described inflammation marker S100A8, together with other proteins, showed a 
differential expression between the inflammatory and OA synovia. Using an alternative 
approach in which transcriptomics (using gene microarrays) and proteomics were combined 
(using multi-Western PowerBlot), Lorenz et al described 58 differentially expressed proteins 
between RA and OA synovial samples [63]. Among these, the protease cathepsin D showed 
marked down-regulation in RA when compared to OA tissues.  
   
2.3.2 Cartilage 
Cartilage is a very attractive tissue to molecular biologists, as it contains only a single cell 
type. At the same time, it forms a major challenge for proteome analysts. This single cell type 
comprises only 1% of the total volume [64], while the main components of the cartilage tissue 
are highly abundant extracellular matrix (ECM) proteins (proteoglycans and collagens). 
Recently, protein profiles of human articular cartilage were determined using a combination 
of 1-DE prefractionation and LC-MS/MS [65] or using a 2-DE approach preceded by an 
extensive sample preparation procedure [66]. A proteome map of cultured human 
chondrocytes was presented by Ruiz-Romero et al. [67], followed by the study of the 
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 subcellular proteome of cultured chondrocyte mitochondria [68]. All these studies revealed 
interesting information, and provided new insights in the protein content of the ECM and 
chondrocytes. However, no comparison was made between healthy and diseased samples. 
Such differential proteome analysis of proteins secreted by cultured chondrocytes revealed 
novel potential regulatory molecules for articular cartilage, such as inhibin betaA [69]. Our 
own group performed a 2-DE based differential proteome analysis to compare protein 
expression patterns of cultured normal chondrocytes versus OA chondrocytes. A marked 
cleavage of vimentin in OA samples was detected by the 2-DE analysis. Subsequent 
validation experiments clearly pointed to distortion of the vimentin organisation associated 
with OA. In addition, novel players were identified in processes known to be involved in OA 
pathogenesis, such as oxidative stress, apoptosis and metabolic activation ([70], in press). 
Undoubtedly, the results generated by such differential analyses will further contribute to our 
knowledge of processes activated in OA-chondrocytes.   
 
3. Future perspectives 
Large scale protein analyses are being conducted on a variety of biological material affected 
in degenerative and inflammatory joint pathologies. This translational research field aims to 
identify new biomarkers (for patient stratification, prediction of therapeutic response, disease 
progression, …) and to gain insight in these complex multifactor diseases, which may assist in 
rational drug development.  
The above discussed studies, resulted in the identification of several potentially interesting 
proteins. However from the therapeutic point of view, integrated approaches, combining 
proteome results with disciplines as RNA-interference and interactomics are needed to asses 
the biological value of the presented candidates. Only in this way, the aim of translating 
proteomics from bench to bedside will be achieved at the level of rational drug development.  
From the biomarker perspective, it is absolutely crucial to set out definite goals for each study 
conducted and to use clinically well defined samples. A major issue herein is the definition of 
the methods used for serum preparation, as it is generally known that the peptide signature of 
serum samples is influenced by the method used for serum preparation [71]. Another issue is 
the isolation of synovial fluid: if the isolation is not well performed, blood contamination may 
become an issue skewing the results. The definition of standard methods would greatly 
enhance the transparency of the obtained data.  
For the future, we feel that there are two important issues that should be set out in this field:   
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 First of all, for serological markers and auto-antigen discovery it is of the utmost importance 
to be able to identify the in vivo epitope against which the antibodies react. For example, in 
the case of citrullination, it is still unknown what the in vivo citrullinated status of the proteins 
in the joint is. Although it is possible to visualize citrulline containing proteins by specific 
detection methods [72], the specific residues which are citrullinated residues in these proteins 
remain to be localised. Proteome analysis combined with mass spectrometry could elucidate 
the in vivo citrullinome in the joint of several rheumatic diseases and bring us one step closer 
to understanding how these post-translational modifications are implied in the pathology.   
Secondly, biomarker research in the field of rheumatology is often conducted on samples 
derived from OA and RA patients. The possibility to discriminate between a non-
inflammatory and inflammatory pathology is important but can be achieved by other means, 
primarily on radiographic and histological features. The true goal of translational research in a 
rheumatic setting should lie, in our opinion, in the ability to find biomarkers to distinguish 
interrelated inflammatory joint pathologies which are still very difficult to discriminate.     
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 Abstract 
The articular cartilage is a highly specialized tissue, extremely well adapted to take up and 
distribute load associated with joint use. Osteoarthritis is the most common disease that 
affects this tissue. One of the major hallmarks of this disorder is the slowly progressive 
degeneration of the cartilage matrix, ultimately leading to joint failure. A substantial amount 
of knowledge is available about processes associated with osteoarthritis. Unfortunately, at this 
time this information did not result in the availability of sufficiently satisfactory disease-
modifying drugs.  
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 1. Articular cartilage, a highly specialized tissue 
Osteoarthritis (OA) is primarily a disease of the articular cartilage. Articular cartilage is a 
specialized tissue that forms the smooth, gliding surface of diarthroidal joints. Diarthroidal 
joints (also called synovial joints) permit a variety of movements and have a joint cavity 
between the articulating bones (figure 3). The articular cartilage is bathed in the synovial fluid 
that serves, together with the vasculature of the subchondral bone, as a nutrient source for the 
chondrocytes. Cartilage consists of an aneural, avascular and alymphatic extracellular matrix 
(ECM), which is synthesized by the sparsely distributed cells, the chondrocytes [73]. In 
human adults, these chondrocytes are considered as terminally differentiated cells which are 
relatively metabolic inactive [74]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Simplified, schematic representation of a knee joint. (Obtained from www.healthcare.utah.edu) 
 
The major constituents of the extracellular cartilage matrix are water, proteoglycans and 
collagens. Proteoglycans are formed by a protein core with glycosaminoglycan side chains, 
mostly keratan sulphate and chondroitin sulphate. Aggrecan is the most abundant 
proteoglycan. Large aggrecan monomers (200-300 kDa core protein) interact with hyaluronic 
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 acid resulting in proteoglycan aggregates. They constitute the nonfibrillar component of the 
cartilage matrix (Figure 4). Together with aggrecan, collagen type II is the most abundant 
matrix molecule. Collagen type II forms, together with less abundant collagens, the fibrillar 
matrix, providing compressive stiffness [75]. Next to these constituents, a whole scale of less 
abundant matrix components is present, such as fibronectin, tenascin, thrombospondin,… 
These components give rise to a tissue extremely well adapted to take up and distribute load 
with minimal deformation. These complex organisations are assembled outside the 
chondrocyte in the extracellular environment. The chondrocytes are dispersed throughout this 
matrix and tightly control this complex network of biomolecules.  
The ECM in adult cartilage is organized in several compartments [76]. The pericellular matrix 
is located immediately adjacent to the chondrocytes. More distal from the chondrocytes is the 
territorial matrix, which composes, together with the pericellular matrix, the cell-associated 
matrix (CAM). The metabolically most inert zone of the articular cartilage is the 
interterritorial matrix. All of these individual zones differ in composition and organisation of 
the matrix compounds. As stated before, chondrocytes are the only resident cells in the 
cartilage and are considered to be terminally differentiated cells that maintain the cartilage 
matrix, at least under normal conditions of low turnover [15]. The turnover rate of collagen is 
very slow in contrast to the proteoglycans, which are continually resynthesized. The 
homeostasis of the extracellular matrix (ECM), mainly depends on the response of the 
chondrocyte to autocrine and paracrine anabolic and catabolic processes, which will be 
discussed later.  
 
 
 
 
 
 
 
 
 
Figure 4: Schematic presentation of the major ECM compounds of articular cartilage. Obtained from 
www.peprotech.com 
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 2. Osteoarthritis: Clinical perspective and current treatment options 
2.1 Definition of OA 
In 1995 the following consensus definition was proposed to define osteoarthritis: 
“Osteoarthritic diseases are a result of both mechanical and biologic events that destabilize the 
normal coupling of degradation and synthesis of articular cartilage chondrocytes and 
extracellular matrix, and subchondral bone. Although they may be initiated by multiple 
factors, including genetic, developmental, metabolic, and traumatic, OA diseases involve all 
of the tissues of the diarthrodial joint. Ultimately, OA diseases are manifested by 
morphologic, biochemical, molecular, and biomechanical changes of both cells and matrix 
which lead to a softening, fibrillation, ulceration, loss of articular cartilage, sclerosis and 
eburnation of subchondral bone, osteophytes and subchondral cysts. When clinically evident, 
OA diseases are characterized by joint pain, tenderness, limitation of movement, crepitus, 
occasional effusion and variable degrees of inflammation without systemic effects.” [77].  
 
2.2 Epidemiology and risk factors of OA 
Osteoarthritis (OA) is a major health problem throughout the western world. For example, the 
prevalence of knee-OA has been estimated to be between 28-34 % in Spain [78]. Associated 
herewith, is a major cost. Because of longer working careers and the relative high frequency 
of osteoarthritis in middle-aged persons, OA results in a considerable loss of time at work and 
early retirement [79]. For instance, the estimated direct cost of OA in France was 1.64 billion 
euros in 2001 [80].  
Prevalence and severity of OA parallel age in most individuals. It is assumed that almost 
everyone shows radiographic changes of knee-OA after the age of 75. However, most 
individuals are non-symptomatic. Next to age, several other risk factors have been associated 
with the development of OA such as sex, ethnic characteristics, bone density, genetics, 
estrogen replacement therapy, obesity, muscle weakness,… [58]. For example, before 50 
years of age, the prevalence of OA in most joints is higher in man than in women. The 
opposite is true after the age of 50. However, hip OA is more frequent in men [79]. Another 
example is obesity, which is probably one of the most important risk factors. Obese subjects 
are at very high risk to develop knee-OA [81]. Given the rise in average body weight in recent 
decades [82], it may be expected that obesity related knee OA will increase in number as in 
severity in the near future. Not surprisingly, several studies showed that weight reduction may 
result in a relief of symptoms associated with OA (reviewed in [83]). 
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 In recent years, several groups performed gene polymorphism studies to unravel genes 
associated with the susceptibility to OA. Efforts have been exercised to associate gene 
polymorphisms in ECM structural protein genes with OA-susceptibility. However, most 
reports provide little or no evidence for such association. In contrast, polymorphism in genes 
encoding proteins that have a regulatory function showed promising results (reviewed in 
[84]). The group of Ikegawa performed several population studies in Asian people and 
identified associations of several gene polymorphisms (GDF5 [85], a growth factor of the 
BMP-2 family;  CALM1 [86], a gene involved in signal transduction; and ASPN [87], which 
has been shown to modulate the expression of collagen type II and aggrecan) with the 
susceptibility to OA. In addition, a large scale multi-center study indicated a role for genes 
encoding the cartilage matrix proteins COMP and COL2A1, an antagonist of Wnt signaling 
(FRZB) and the ASPN gene. Furthermore, this study emphasized the variation between 
populations and sexes [88]. This variation was confirmed in an additional study, highlighting 
the heterogeneous nature of OA genetic susceptibility [89]. Finally, these and several other 
groups published additional genes which might be associated with OA, among these are the 
IL-4R [90] and IL-17 [91] genes. 
Whereas OA has long been considered as being a result of trauma or age, it is now generally 
accepted that the etiology of OA is multiple and includes various mechanical, biochemical 
and genetic factors [74].  
 
2.3 Clinical features 
From a clinical perspective, this pathology is typically associated with pain that occurs with 
joint use. The most prominent sources of pain are the bone, synovial inflammation and a 
stretched joint capsule filled with fluid. After all, the pathology of osteoarthritis affects all 
structures within a joint: The characteristic structural changes associated with the 
development of OA include a progressive loss of articular cartilage, increased subchondral 
plate thickness, formation of new bone at the joint margins (osteophytes) and the development 
of subchondral cysts [92] (figure 5a). Furthermore, in some patients synovitis and lesions in 
the bone marrow may develop. Such macroscopic structural changes are usually observed by 
radiography and may be used as a confirmation in the diagnosis of OA (figure 5b).  In the 
recent decade, another imaging technique, magnetic resonance imaging (MRI), has evolved to 
a very promising diagnostic tool for diagnosis as well as follow-up of disease progression 
[93]. Localized areas of loss of cartilage can increase focal stress across the joint, leading to 
further cartilage loss, creating a vicious cycle of joint damage that ultimately can lead to joint 
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 failure [94]. OA is generally considered to be a disease of the articular cartilage. However, a 
recent editorial suggests that abnormalities in the surrounding environment (ligaments, bone, 
nerves, meniscus and muscles) are at least as important targets for the development of 
disease-modifying therapy for OA as the cartilage [95]. In conclusion, it may be suggested 
that the degenerative process in the articular cartilage may be initiated in a variety of ways 
and by a variety of joint constituents, as any constituent of the joint may affect the other.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Next to articular cartilage degeneration, other macroscopic changes such as the development of 
osteophytes may be observed. Figure 5a (left panel): Schematic representation of an OA-affected knee at the 
medial side (adapted from [94]). Figure 5b (right panel): Radiograph showing cartilage degeneration of the 
medial side of the knee. White arrow indicates narrowing of the medial joint space; black arrow indicates the 
formation of osteophytes. (obtained from [94]). 
 
2.4 Current treatment options for OA 
Today, there is no known cure for OA of the knee or hip. The major goal of current treatments 
is to control pain and to improve quality of life. The analgesic acetaminophen is generally 
considered as an initial treatment option, based on its overall cost, efficacy and toxicity [96]. 
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 Compared to NSAIDs, acetaminophen is as efficient in pain relief in patients with mild to 
moderate pain [97, 98]. Even though, acetaminophen often fails to control pain beyond that of 
the mild or moderate degree. Therefore, in patients with moderate-to-severe pain, and in 
whom signs of joint inflammation are present, a NSAID or joint aspiration combined with an 
intra-articular injection of glucocoarticoids is a valuable alternative as an initial approach 
[99]. Recently, a group of ‘nutraceuticals’ (mostly glucosamine or chondroitine sulphate) 
have been proposed as alternative therapies for OA. The information concerning the efficacy 
of these products is contradictory and greatly depends on the study design. The use of 
glucosamine as a therapy for OA has been reviewed [100] and some data suggest that these 
nutraceuticals may improve the symptoms of OA. However, due to sparse data, further studies 
are absolutely warranted [101]. A recent multi-center, double-blind, placebo- and celecoxib-
controlled study (the GAIT-study) showed that glucosamine and chondroitin sulphate alone or 
in combination did not reduce knee pain effectively in the overall group of patients. However, 
exploratory analyses suggest that the combination of both may be effective in a subgroup of 
patients with moderate-to-severe knee pain [102]. ACR-guidelines suggest that all of these 
pharmacological treatments should be considered as additives to nonpharmacological 
measurements such as physical therapy, weight loss, patient education,… [99]. Next to the 
ACR-guidelines, the EULAR proposed its own guidelines for OA-management depending on 
the affected joint: hand [103], hip [104] or knee (see table 1) [105] . If patients with severe 
symptomatic OA do not respond to medical therapy and if OA is associated with impairments 
to their quality of life, several orthopaedic surgery options may be available. For example, 
total joint replacement is among the most effective of all medical interventions; the pain and 
disability of end-stage OA can be eliminated, restoring the patients to near-normal function 
[106].  
In conclusion, a whole scale of symptom relieving drugs and therapies are available. 
However, today there are no drugs on hand which show sufficiently satisfactory disease 
modifying activity [107]. Hopefully, current and future research will provide new insights in 
this complex disease and will assist in the rational development of such drugs. 
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 Table 1: Final set of 10 recommendations based on both evidence and expert opinion for the management of 
knee OA, proposed by the EULAR Standing Committee for International Clinical Studies Including Therapeutic 
Trials [105]. 
1 The optimal management of knee OA requires a combination of non-pharmacological 
and pharmacological treatment modalities  
2 The treatment of knee OA should be tailored according to:  
 (a) Knee risk factors (obesity, adverse mechanical factors, physical activity)  
 (b) General risk factors (age, comorbidity, polypharmacy)  
 (c) Level of pain intensity and disability  
 (d) Sign of inflammation—for example, effusion  
 (e) Location and degree of structural damage  
3 Non-pharmacological treatment of knee OA should include regular education, exercise, 
appliances (sticks, insoles, knee bracing), and weight reduction  
4 Paracetamol is the oral analgesic to try first and, if successful, the preferred long term 
oral analgesic  
5 Topical applications (NSAID, capsaicin) have clinical efficacy and are safe 
6 NSAIDs should be considered in patients unresponsive to paracetamol. In patients with 
an increased gastrointestinal risk, non-selective NSAIDs and effective gastroprotective 
agents, or selective COX 2 inhibitors should be used  
7 Opioid analgesics, with or without paracetamol, are useful alternatives in patients in 
whom NSAIDs, including COX 2 selective inhibitors, are contraindicated, ineffective, 
and/or poorly tolerated  
8 SYSADOA (glucosamine sulphate, chondroitin sulphate, ASU, diacerein, hyaluronic 
acid) have symptomatic effects and may modify structure 
9 Intra-articular injection of long acting corticosteroid is indicated for flare of knee pain, 
especially if accompanied by effusion 
10 Joint replacement has to be considered in patients with radiographic evidence of knee 
OA who have refractory pain and disability 
 
3. Pathogenesis of OA: biomolecular perspective 
3.1 Cytokines and growth factors: the guardians of chondrocyte homeostasis? 
As stated above, the matrix forms the functional component of the articular cartilage, whereas 
the chondrocytes are responsible for the homeostasis of this tissue. The extracellular matrix 
also forms the micro-environment for the chondrocytes, containing cytokines and growth 
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 factors synthesized by the chondrocyte itself. In healthy adults, articular cartilage shows a 
slow tissue turnover and remodeling, based on an equal balance between anabolic and 
catabolic cytokines and growth factors. With respect to regulation of the chondrocyte 
function, it is possible to classify the cytokines that regulate cartilage remodeling as catabolic 
cytokines (which ultimately results in enhanced matrix degradation) and anabolic cytokines, 
(which act as growth and differentiation factors).  In addition, several cytokines can be 
classified as modulatory cytokines, based on their capacity to modulate the activities of other 
cytokines, for example IL-6 and IL-11 (table 2) [108]. 
 
Table 2: The most prominent cytokines and growth factors involved in cartilage metabolism. 
Catabolic  Modulatory Anabolic 
Interleukin-1 (IL-1) Interleukin-6 (IL-6) Insulin-like growth factor 1 
(IGF-1) 
Tumor necrosis factor α 
(TNF-α) 
Interleukin-8 (IL-8) Transforming growth factor 
β (TGF-β) 
Interleukin-17 (IL-17)  Bone morphogenetic proteins 
(BMP) -2, 4, 6, 7, 9, 13 
Interleukin-18 (IL-18)  Fibroblast growth factors 
(FGFs) 
 
The best known catabolic cytokines are interleukin-1 (IL-1) and tumor-necrosis factor α 
(TNF-α). Studies, both in vitro and in vivo, show that the effects of IL-1 and TNF-α are 
similar or synergistic. It is well established that IL-1 contributes to the depletion of the 
cartilage matrix by decreasing the synthesis of cartilage-specific collagens and proteoglycans 
(reviewed in [108-110]).  It is now generally accepted that these cytokines are involved in the 
matrix degradation associated with OA [108], as pathways associated with IL-1 and TNF-
α seem to be activated in OA. Moreover, OA cartilage appears to be more susceptible to the 
degenerate effects of IL-1 [111] and TNF-α. For example, OA chondrocytes express more of 
the TNF-receptor than nonarthritic chondrocytes  [112] and this receptor has been localized in 
cells at sites of focal loss of proteoglycans in OA cartilage [113]. On the other hand, an 
increased expression of the IL-1 receptor type I has been detected in OA chondrocytes in 
association with an enhanced production of matrix-metalloproteinases (MMPs) [114]. The 
MMPs are a family of proteases which play, together with the aggrecanases, a primary role in 
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 the degradation of the extracellular matrix [115]. In recent years, a body of knowledge has 
become available concerning the mediators (such as NO and prostaglandins [116], matrix-
metalloproteinases (MMPs) [117, 118]) and signal transduction pathways activated by these 
cytokines (for example nuclear factor-κB-mediated pathways [119, 120]). Other known, less 
characterized, catabolic cytokines in chondrocyte biology are IL-17 [121] and IL-18 [122]. 
Next to catabolic cytokines, there is a scale of anabolic factors which play an important role in 
both the preservation of normal articular cartilage and its failure in joint disease. Insulin-
growth factor I (IGF-I) was among the first to be identified as an anabolic factor [123-125]. 
Transforming-growth factor β regulates a variety of cellular responses on the chondrocyte, via 
distinct pathways. For example, it has been shown to induce collagen type II expression in 
human articular chondrocytes [126]. However, the effects of TGF-β on chondrocyte 
metabolism seem to be rather contradictory, given the observation that some groups reported 
catabolic effects of TGF-β on cartilage (reviewed and discussed in [127]).  Bone 
morphogenetic proteins (BMPs) are also considered as anabolic factors, especially BMP-2 
and BMP-7, have been widely investigated and are known to maintain and promote the 
articular chondrocyte phenotype in vitro [128]. It has even been stated that no other growth 
factor equals the capacity of BMP-7 to produce a marked upregulation of the majority of 
ECM compounds [127]. Finally, a number of reports showed synergistic effects of different 
anabolic factors on chondrocytes [129-131]. 
 
In recent decades, several proteins have been elucidated which may influence the activity of 
these cytokines or their downstream “effectors” directly. In consequence, these proteins are 
essential to maintain the homeostasis in normal chondrocytes and may play a role in the 
pathogenesis of OA. Moreover, the expression of these modulators can be controlled by one 
or more of these cytokines or growth-factors. The action of IGF-1 on chondrocyte metabolism 
can be regulated by the presence of extracellular, high-affinity IGF-binding proteins (IGFBP), 
which modulate the interaction of IGF-1 with its receptor [132]. Alternatively, the IL-1 
receptor II, which acts as a decoy receptor and whose expression is controlled by IGF-1, may 
reverse the catabolic activity of IL-1 on chondrocytes [133]. Another example are the tissue 
inhibitors of metalloproteinases (TIMPs): these act as inhibitors of MMPs. The expression of 
these inhibitors and binding proteins is also regulated by cytokines or growth factors [134-
136], which may explain the very complex and very delicate balance between catabolic and 
anabolic processes in the chondrocyte. 
37
 3.2 The role of the chondrocyte in the pathogenesis of OA 
The development of OA is associated with changes in the interterritorial matrix (more 
specifically changes in the collagen network and the interwoven proteoglycan aggregates), the 
cell-associated matrix (for example transformational conformation of resident type VI 
collagen) as well as in the cellular phenotype [137]. The chondrocyte has clinical importance 
in the context of OA pathogenesis, which results from a failure to maintain the balance 
between synthesis and degradation of the ECM (for a review see [138]). Therefore, it is 
generally believed that chondrocytes play important roles in the development of OA [139]. In 
early OA, the chondrocyte exhibits a transient proliferative response (clonal growth) [140], an 
increased synthesis of cartilage matrix in an attempt to repair cartilage breakdown [141, 142] 
and an increased expression of catabolic cytokines [143] and matrix-degrading enzymes such 
as matrix metalloproteinases [117] and aggrecanases [144] (reviewed in [145]). The cellular 
reaction during OA-development is pleiomorphic at different stages. First, next to an 
increased proliferation rate, it has also been suggested that cell death is a central feature in OA 
cartilage degeneration [146]. Apoptotic cell death has been reported as a major event in OA 
[147-149]. However, there are some contradictory viewpoints concerning the importance of 
apoptosis in the pathogenesis of OA [137]. Furthermore, despite an increased synthetic 
activity for extracellular matrix components in OA [142, 150], there is a net loss of functional 
cartilage matrix. It may be concluded that the OA-chondrocyte undergoes phenotypic 
alterations, which may represent a potential reason for the anabolic failure of chondrocytes in 
OA: despite the potential high synthetic activity, OA-chondrocytes may express other -less 
functional- genes. This changed phenotype ultimately results in the appearance of 
macroscopic phenomena such as fibrillations, matrix depletion, cell cluster formation and 
changes in quantity, distribution, or composition of matrix proteins [151]. 
In conclusion, it may be stated that the cellular activity of chondrocytes in OA is very 
complex and may vary during the course of the disease. As described above, a lot of 
knowledge is available at the biomolecular level. However, the big question remains: “What 
is/are the first step(s) in the initiation of cellular dysregulated activity in OA?” [139].  
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 Abstract 
Proteomics, the large-scale analysis of proteins of a given cell or tissue, is a fast emerging 
field in biomedical research. It has become clear that proteomic approaches can assist in 
unraveling complex disease pathways and in the discovery of protein drug targets. The recent 
flood in proteomic-data demonstrates the furious digging in the quest for the so called “Holy 
Grail”. At present, however, only a limited number of reports describing proteomic studies in 
rheumatology have been published. This review highlights some recent advances in the field 
of proteomic techniques. These new techniques as well as classic approaches have potential 
applications in the field of rheumatology. There is little doubt that these and upcoming new 
proteomic tools will lead to landmark discoveries in this field with applications ranging from 
diagnostics, therapeutic monitoring to discovery of new therapeutic targets.   
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 1. Introduction 
The human genome sequencing has led to a revolution in molecular biology research. The 
analysis of the human genome introduced the large-scale, ‘-omics’ disciplines. Disciplines as 
genomics, transcriptomics, proteomics and metabo(l)/(n)omics have been developed in the 
recent decades and are characterized by an exponential growth over the past years. All these 
disciplines focus on a different level (DNA, mRNA, proteins, metabolites) in cell biology, 
making them complementary to each other. The insight that one gene can encode different 
protein isoforms made researchers realize that a genomics approach provides limited 
information in the global analysis of gene products. Several phenomena such as protein 
structure, protein modifications, protein function and protein-protein interactions, can only be 
studied at protein level. Proteomics is one of the fastest emerging fields in these ‘omics’ 
disciplines. An explanation for this flood of proteomic-data is that proteins are very attractive 
drug targets as they are the main executers of cellular function. Nowadays, almost all drugs 
have protein targets.  
The general goal of proteomics can be described as the aim to obtain a more global and 
integrated view of biology by studying all the proteins of a cell rather than each one 
individually [152]. Three main areas can be discriminated in proteomics: the large-scale 
identification of proteins and post-translational modifications (PTMs), ‘differential display’ 
proteomics for comparison of protein levels in a wide range of diseases and studies of protein-
protein interactions [153]. These three areas reveal different information and a combination of 
all is necessary to provide new insights in our understanding of biological processes.   
 
1.1 The combination of ‘new’ and ‘established’ technologies opens up new perspectives   
A whole scale of techniques has become available to investigate the proteome of biological 
samples. For a detailed overview of the most prominent techniques in proteomics see 
reference [152]. In this review, we will focus on the most widely applied techniques in the 
field of rheumatology and recent advances will be highlighted. 
 
1.1.1 Two-dimensional gel electrophoresis 
Two-dimensional gel electrophoresis (2-DE) remains the most important tool of a classic 
proteomic approach. 2-DE was first described in 1975 by O’Farrell [154] and Klose [155]. It 
enables the separation of complex mixtures of proteins, based on the isoelectric point (pI) in 
the first dimension and on the molecular weight (MW) in the second dimension. A 2-DE 
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 approach consists of several steps: sample preparation, protein separation, protein detection, 
image analysis and protein identification (Figure 6).  
 
Figure 6: Overview of a classic two-dimensional gel approach for differential protein expression profiling. 
Proteins are extracted from cells (or tissues) in different conditions. The solubilized proteins are applied to a gel 
strip and separated according to their pI, which is usually performed in an immobilized pH gradient. After 
reduction and alkylation of cysteine residues, the strip is applied to a SDS-PAGE gel. The denatured proteins 
migrate in the applied electrical field and are separated based on their molecular weight. Gels are stained and 
imaged to visualize proteins. Protein spots are quantified and matched to each other with the appropriate 
software. Spots quantities are subjected to statistical analysis, resulting in a list of interesting protein spots. These 
spots can then be excised and subjected to mass spectrometry for identification. 
 
The current state in 2-DE technology has been reviewed in [156]. Here, we will highlight 
some interesting and recent advances in this ‘old-fashioned’, but still ‘golden-standard’ 
technology. 
One of the biggest challenges in proteome-analysis is the identification of lower abundant 
proteins, as these ‘hidden’ proteins may be the interesting ones (e.g. membrane receptors). 
Nowadays a wide range of sample preparation methods are applied resulting in higher 
dynamic ranges, the ability to resolve hydrophobic and acidic or basic proteins. Methods 
based on subcellular fractionation [157], depletion of highly abundant proteins [158], 
alternative solubilizing agents [159] and differential extraction [160] are widely used and 
have proven their efficiency. Such pre-fractionation methods aim to reduce the complexity of 
the sample and thereby revealing minor abundant proteins. Moreover, methods based on 
Image 
analysis 
Sample Preparation 
Protein separation according 
to pI and MW/Protein 
visualization 
Excision of interesting spots 
Identification by mass 
spectrometry as shown 
in Figure 2 
p
M
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 subcellular fractionation provide interesting information about protein localization. It has to 
be noted that prefractionation methods based on the depletion of highly abundant proteins 
(e.g. albumin in serum samples), can result in the loss of low abundant proteins bound to these 
carrier proteins. As those may act as a reservoir for bound biomarkers [161], depletion 
methods may result in the lost of important information. For a detailed review on sample 
preparation methods in proteomics, see references [162] and [163].  
Since the introduction of 2-DE, tremendous improvements have been made. In particular, the 
introduction of immobilized pH gradients (IPG) [164], narrow-range pH IPG-strips [165] and 
fluorescent stains (reviewed in [166]) led to superior results in terms of resolution, sensitivity 
and reproducibility. For example, the linear dynamic range of Sypro Ruby reaches from 1-2 
ng to 1-2 µg (8 to 60 ng for silver staining) [167]. Recently, sensitive fluorescent stains, 
which selectively stain phosphorylated [168] or glycosylated [169] proteins, have been 
introduced. The greatest power of 2-DE is the ability to resolve multiple isoforms of a protein, 
which differ in only a minor pI- or MW-value. As it is known that PTMs can influence 
protein activity, the use of a high-resolution 2-DE approach combined with the above 
mentioned fluorescent stains and recent advances in mass spectrometry (which will be 
discussed later in this review) can open a new era in the application of 2-DE.  
As high accuracy in spot detection and matching is required to avoid artifacts, image analysis 
is a critical step in the ‘2-DE process’. The introduction of high-resolution scanners and 
specialized software facilitated spot detection, matching and quantification. Nevertheless, this 
step remains one of the most time-consuming steps in a classic proteomic approach. Advances 
herein, have been made by difference gel electrophoresis (DIGE) [170]. This technology is 
based on the fluorescent tagging of two protein samples with two different dyes (cyanine 
dyes: Cy3 and Cy5) prior to electrophoresis. The samples are mixed and can be run on the 
same gel. Fluorescence imaging of the gel is used to create separate images, which can be 
ideally superimposed. Moreover, a third color that represents an internal standard, a mixture 
of all samples labeled with Cy2, has been introduced to reduce inter-gel variability [171].  
 
1.1.2 Mass spectrometry 
The application of mass spectrometry (MS) in protein analysis was a milestone in the field of 
proteomics. The discovery of ‘soft’ ionization techniques electrospray-ionization (ESI) and 
matrix-assisted laser desorption/ionization (MALDI) made it possible to analyze 
biomolecules. In a classic 2-DE approach, spots of interest are excised and treated with a 
proteolytic enzyme (e.g. trypsin) to produce a mixture of smaller peptides. The identification 
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 of the unknown protein is based on the analysis of this peptide mixture (Figure 7). The 
detection limit of an MS-based approach is mainly limited by the sample preparation method. 
In general, for successful mass spectrometric identification of an in-gel digested protein, 
Sypro Ruby-stained amounts (low ng-range) are necessary. Using gel-free sample preparation 
methods (see 1.1.3) lower detection limits can be achieved. The most common technique to 
identify proteins is called peptide mass fingerprinting. As the peptide mixture is submitted to 
‘single MS’ mass spectrometry (usually MALDI Time-Of-Flight (MALDI-TOF)), this yields 
a set of accurate mass-to-charge ratios of each peptide. This ‘mass fingerprint’ is then 
compared to theoretically expected peptide masses for each protein in a given protein 
sequence database. Alternatively, ‘tandem MS’ mass spectrometry (MS/MS) determines not 
only the mass of the peptide but yields also information about the amino acid sequence. In 
MS/MS mode a survey scan is performed after which a peptide is selected by the first mass 
analyzer and dissociated by collision with gas molecules, the so-called collision-induced 
dissociation (CID). This results in the fragmentation of the bonds along the peptide backbone. 
The tandem MS spectrum contains structural information related to the peptide sequence. 
Therefore, these searches are generally more specific than peptide mass fingerprinting. In 
contrast to peptide mass fingerprint data, these fragmentation data can also be submitted to 
nucleotide databases, such as expressed sequence tag databases (EST). Whether a single MS 
or a tandem MS approach is used, the identification is related to a certain score which is a 
measure for the level of confidence for the match between the spectra and theoretical 
sequence data. An extended description of MS in protein and peptide analysis is beyond the 
scope of this review, but is reviewed in detail in reference [172].  
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Figure 7: Strategies for mass spectrometric identification of protein spots of interest. After spots have been 
excised, proteins are digested. This is usually done by site specific proteases (e.g. trypsin cleavage results in 
peptides with arginine or lysine at the C-terminus). The resulting peptide mixture can be subjected to mass 
spectrometry. A: Using a Peptide Mass Fingerprinting (PMF) approach, the mass spectrometer (usually MALDI-
TOF) generates a list of peaks indicating the mass-to-charge ratio of the peptides. This set of masses is compared 
with theoretically expected peptide masses for each protein in a database. Depending on the number of peptide 
matches, the search engine will return a score which is a measure for the level of confidence for the match. B: In 
a first step a survey scan is recorded by the mass spectrometer (usually ESI QqTOF). The resulting spectrum 
usually displays both singly and multiply charged species. A parent ion of interest is selected and subjected to 
collision-induced dissociation (CID). This results in a random dissociation of the peptide along the peptide 
backbones, yielding the so-called y and b ions. Mass differences between consecutive y or b ions are 
representative for a certain amino acid. Experimental MS/MS-spectra can be matched against theoretical 
MS/MS-spectra for the peptides present in a given database. Only a short ‘sequence tag’ can be sufficient to 
identify a certain protein.  
 
1.1.3 ‘Gel-free’ methods 
As one of the major disadvantages of 2-DE is that high molecular weight proteins and 
extremely acidic or basic proteins are lost, methods were developed to omit 2-DE gels. In 
recent decades, chromatography- and MS-technologies have improved in a staggering way. 
Powerful chromatographic methods (based on liquid chromatography (LC)) and mass 
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 spectrometry were successfully combined in the field of large-scale identification of proteins 
and their post-translational modifications. In the recent decade, multidimensional LC-MS/MS 
technologies were introduced.  A whole cell lysate is digested chemically or by a protease. 
This very complex mixture of peptides is separated by multidimensional separation 
techniques and applied to MS/MS-analysis. These multidimensional separation techniques 
consist of a combination of size-exclusion, reversed-phase and/or ion-exchange 
chromatography. In this context, the group of Yates introduced the multidimensional protein 
identification technology (MudPIT), in which reversed-phase chromatography and strong 
cation-exchange chromatography were combined [173]. This allowed the identification of 
low-abundant proteins, such as transcription factors, demonstrating the possibility to identify 
proteins below the detection limit of a classic 2-DE approach. Such multidimensional 
approaches have also been used for large-scale protein phosphorylation analysis. Beausoleil et 
al [174] detected over 2000 phosphorylation sites in the nuclear fraction of HeLa cell lysates 
by a combination of strong-cation exchange chromatography and reverse-phase LC-MS/MS. 
Such large-scale analysis of protein phosphorylation can help to identify new kinase targets 
and provide new insights in signaling pathways. 
Such approaches are interesting for the exploration of the proteome of a given cell-type or 
tissue. But, they do not allow direct quantification or comparison between different samples. 
Therefore, alternative strategies have been developed in the field of ‘gel-free’ differential 
protein expression profiling. Stable isotope labeling of samples allows for direct relative 
quantitative analysis by MS. The principle of these methods is based on the incorporation of a 
stable isotope in one of the two samples to be compared. As the measured peaks of the treated 
sample shifts with a known mass, a relative quantitative measurement is possible between the 
two samples, as determined by the peak ratio. Stable isotopes can be incorporated by 
incubation in a medium enriched with stable isotopes (e.g., 15N) [175], alternatively the 
incorporation can be done in vitro by protein or peptide derivatization. Isotope coded affinity 
tags (ICAT) allow relative changes to be determined by MS and is based on the attachment of 
an isotope label on cysteine [176]. A recently introduced and very promising method in 
quantitative gel-free proteomics is iTRAQ, which allow relative changes to be determined in 
MS/MS. This method is based on the incorporation of different isobaric mass labels (at the N-
terminal and lysine side chains of peptides) in different samples. The reagents are 
differentially isotopically labeled such that a given derivatized peptide in all samples is 
isobaric and indistinguishable by chromatography, but yield different reporter ions in MS/MS 
(following CID) that can be used to identify and quantify individual samples [177]. One of the 
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 major advantages of this technique to other labeling methods is that it does not increase 
complexity in MS-mode as the tags are isobaric. In combination with protein quantitation, 
labelling strategies may also be used to analyze protein processing by selective labeling of the 
N-terminus of the protein [178]. 
Another development in biomarker analysis is surface-enhanced laser desorption/ionization 
(SELDI-TOF-MS), which is especially useful in the analysis of the low-molecular weight 
proteome. Whereas the smallest proteins detected by 2-DE are about 10 to 15 kDa, SELDI 
enables the analysis of peptides and proteins ranging from 500 Da to 20 kDa and thereby the 
exploration of the low molecular weight proteome. This technology couples protein 
subspecies enrichment to presentation to the mass spectrometer. Using substrates with varying 
adsorptive properties (e.g., reversed phase resins, cation exchange resins, anion exchange 
resins…) (reviewed in [179]) and the application of various wash buffers, a fraction of the 
proteins can be selected. TOF-MS analysis results in spectra of complex protein mixtures 
based on the mass-to-charge ratio of the proteins. Statistical analysis of peak patterns from 
different disease states can yield multimarker patterns, which can be used to classify the 
samples. A major disadvantage of this approach is that it does not yield sequence information 
to identify the protein of interest. So, once the importance of a marker has been demonstrated, 
further purification, separation and digestion have to be applied for protein identification.   
Finally, the development of array-based proteomic techniques is very promising in routine 
diagnostics as well as in biomarker discovery. Several array types can be distinguished 
(reviewed in[180]). Tissue microarrays (TMAs) are ordered arrays of tissue cores from 
multiple donor blocks, which allow the simultaneous analysis of numerous tissue samples 
with a detection system (e.g. an antibody). Forward-phase protein microarrays (FPAs) consist 
of several bound bait molecules (e.g. antibodies [181]) on the array’s surface. Samples such as 
serum or synovial fluid are applied to these arrays and bound analytes can be visualized by 
direct labeling or by labeled antibodies. Finally, with Reverse-phase protein microarrays 
(RPAs) protein mixtures (e.g. cellular lysates) are spotted directly on the array and probed 
with specific antibodies [182]. The major power of these protein-arrays lies in the ability to 
screen for molecular networks. So, undoubtedly these arrays will contribute to future 
discoveries in signaling cascades associated with disease states. 
 
1.1.4 Protein interaction analysis 
To elucidate a biological function of a protein, the knowledge of its location and level of 
expression is not sufficient. The identification of the interaction partners of a protein is 
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 indispensable to understand cell biology. Methods to study protein complexes are usually 
based on immunoprecipitation reactions. For example, the “bait” protein can be produced as a 
GST-fusion protein and then mixed with a cell lysate. Using GST-affinity purification, the 
“bait” protein and its interactors can be isolated and subsequently identified [183]. 
Alternatively, several other approaches are applicable, such as the yeast two-hybrid system 
[184], phage display and other MS-based approaches (reviewed in [185]). As the study of 
protein-interactions (‘interactomics’) has evolved to a specialized discipline, it will not be 
further discussed in this review. 
 
Countless techniques and variations on these techniques have been developed in proteomics. 
As discussed above, every approach has its own advantages and disadvantages. The choice for 
a specific technique or a combination of different techniques, depends on the application and 
goal of the study. Whereas alternative (e.g. ‘gel-free’) methods are gaining field in the large-
scale identification of proteins and their post-translational modifications, a 2-DE based 
approach remains the method of choice in many laboratories for comparison of protein levels 
in a set of several disease states.  
One of the biggest challenges in the further development of proteomic techniques remains the 
identification of the low abundant proteins. For example, membrane receptors are very 
interesting drug targets, but they are only very rarely identified in a proteome study. Future 
optimization of current techniques and development of new strategies will probably enable 
further ‘digging’ in the human proteome. 
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 Osteoarthritis is the most common disabling condition in the western world. Given current 
life-style and future demographic evolutions, this disease is and will remain to be a major 
health problem [1]. OA is not directly a life-threatening disease. However, it has major impact 
both on the quality of life of the individual patient and on the economy [2]. 
A major hallmark of osteoarthritis is the slowly progressive degeneration of the articular 
cartilage, ultimately leading to distortion of other joint structures. In recent years, it has 
become clear that chondrocytes, the only resident cells in articular cartilage, play a central 
role in the initiation and/or the progression of the disease. As described throughout this study 
a lot of research efforts have already been conducted to study the physiopathology of 
chondrocytes in OA. The boom of biomolecular research in the recent decades is also 
reflected in this domain. However, at this time no sufficiently satisfactory disease-modifying 
drugs are available in the management of OA. A better understanding of underlying 
pathogenic processes may be crucial in the rational development of such drugs.  
 
The primary goal of this study was to identify differentially expressed or abundant proteins 
between chondrocytes isolated from ‘normal’ and OA-patients. In recent years, gel-free 
proteomics techniques have been introduced in differential expression analyses.  However, as 
previously stated in the introduction, a two-dimensional gel electrophoresis approach remains 
a very attractive approach to screen for differentially expressed proteins or protein isoforms. 
Proteome analyses, especially gel-based approaches, enable the identification of post-
translational modifications, such as protein cleavage. In our study, protein patterns of different 
patient groups were compared by 2-D PAGE and potential interesting protein spots were 
identified by mass spectrometry. The differential abundance of a given spot, does not 
necessarily indicate that the corresponding gene is differentially expressed. This was clearly 
reflected in the subsequent validation of two spots identified as vimentin (Chapter III, Part 1). 
These turned out to be cleavage fragments, indicative of cytoskeletal disarrangements. 
 
While the identification of a group of differentially abundant protein spots may provide new 
insights, it remains mandatory to perform additional validation studies to asses the biological 
importance of a potential interesting protein. In the second part of this study, we focussed on 
the potential role of αBcrystallin in the chondrocyte’s biology. Advances in mass 
spectrometry equipment, enabled us to reliably identify this differentially expressed protein 
spot discovered in the first study. Next to the quest for potential inducers/suppressors of this 
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 protein, we investigated its relation with chondrocyte matrix-genes using RNA-interference 
(Chapter III, Part 2). 
 
In recent years, studies have been initiated to disclose the proteome of human chondrocytes 
and cartilage [3-6]. Despite these studies, comprehensive information of the chondrocyte 
proteome remains limited. Especially the membrane and low-abundance proteome remain 
largely unknown. In the third part of this study, the aim was to further explore the proteome 
expressed by human knee chondrocytes, providing novel leads for future biomolecular 
research (Chapter III, Part 3). 
 
All together, this study presents an introduction of proteomics technologies in OA-research at 
the chondrocyte level. The 2-DE analysis provided a platform to identify potentially 
interesting processes associated with OA. By validating the results of such proteome analyses 
with independent and complementary techniques, we aimed to present some candidate 
proteins which may shed a new light on chondrocyte biology and/or OA-pathogenesis. 
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 Abstract 
Objective: We conducted a proteome analysis of human articular chondrocytes, in order to 
identify proteins differentially expressed in chondrocytes during the progression of 
osteoarthritis (OA) and to characterize the phosphorylation status of these proteins.  
Methods: The proteins of 20 samples of human chondrocytes obtained from the cartilage of 
human knees (6 from healthy cartilage (NoNo), 7 from visually intact zones (NoOA) and 7 
from visually damaged zones (OAOA) of OA-cartilage from the same knee joint) were 
sequentially extracted and subjected to two-dimensional gel electrophoresis. Protein 
expression patterns were subjected to statistical analysis and protein spots of interest were 
identified by electrospray ionization tandem mass spectrometry.  
Results: We identified several protein spots, showing a differential expression between the 
sample groups. Cleaved vimentin was upregulated in OAOA samples, this was confirmed by 
1-D electrophoresis and Western blot. The possible impact of vimentin cleavage on the 
chondrocyte’s cytoskeleton was illustrated by confocal microscopy analysis, which revealed a 
distorted vimentin organisation in OA chondrocytes. In contrast, F-actin staining did not 
reveal differences.  
Conclusion: All together, this study revealed substantial alterations in the vimentin 
cytoskeleton in OA-affected human articular chondrocytes.  
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 1. Introduction 
Osteoarthritis (OA) is the most common disabling human condition in the western world, 
which ultimately results in degeneration of the articular cartilage. Now, it is clear that the 
chondrocyte plays a critical role in cartilage degeneration. In the recent years, several studies 
were performed to reveal changes in the cellular phenotype during OA-cartilage degeneration. 
Some of them investigated the expression of single genes by RT-PCR, Western blotting or 
immunocyto- and histochemistry [1-5]. Other studies investigated a broader set of genes using 
cDNA-array technology [6] or antibody microarrays [7]. In a recent study, the gene 
expression profiles of normal cartilage and intact and damaged regions of OA-cartilage were 
compared using cDNA arrays [8]. Despite these studies, the knowledge about the molecular 
mechanism of cartilage destruction in OA can still be improved.  
 
The introduction of proteomics techniques enables the large-scale identification of proteins 
and the large-scale comparison of protein levels in a wide range of diseases. A whole scale of 
techniques has become available to elucidate the human proteome. Nevertheless, two-
dimensional gel electrophoresis (2-DE) is the most widely applied technique to screen for 
differentially expressed proteins. 2-DE can still be considered as the most comprehensive 
analysis method for detecting a wide variety of post-translational modifications (PTMs), for 
example phosphorylation and protein cleavage. In such an approach, proteins are separated 
based on the isoelectric point (pI) in the first dimension and on the molecular weight (Mw) in 
the second dimension. After spot visualization, spot intensities can be compared and spots of 
interest can be identified by mass spectrometry (MS). Recently, some studies describing the 
proteome of chondrocytes [9] or cartilage [10] have been published. However, no comparison 
was made between healthy and OA-affected chondrocytes. Using a 2-DE approach, 
Hermansson et al. [11] investigated the proteins secreted by normal and OA-chondrocytes. 
This study revealed several differentially secreted proteins by OA-chondrocytes, but 
intracellular proteins were not investigated. To gain new insights in the molecular control 
mechanisms, involved in the development of OA, we analyzed the proteome of cultured 
chondrocytes and their cell associated matrix (CAM) from healthy donors and OA-patients. 
Since chondrocytes are the only cells in cartilage, which regulate the normal anabolism and 
catabolism of the cartilage matrix, an alteration in the protein expression pattern of these cells 
can influence the normal matrix homeostasis. The identification of differentially expressed 
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 proteins can help us to identify new players in the progression of OA, to better understand the 
underlying disease-processes and to define novel therapeutic targets in this disease.  
 
Aigner et al. [12] reviewed studies of functional genomics of OA and emphasized the 
importance of such gene expression analysis to evaluate disease hypotheses and understand 
complex diseases such as OA.  However, mRNA levels often do not correlate with protein 
levels and phenomena such as post-translational modifications (PTMs) and protein-processing 
can not be discovered using such transcriptome studies. A proteomic approach, which 
identifies post-translational modifications, differentially expressed proteins or differentially 
processed proteins is a valuable complement to gene-expression studies. 
 
Using two-dimensional electrophoresis, sequential staining procedures and mass 
spectrometry, we were able to identify isoforms of proteins showing an altered abundance in 
chondrocytes isolated from healthy cartilage versus visually intact or degenerated zones of 
OA-cartilage. The combination of these data with Western blot analysis and confocal 
microsocopy revealed a distorted vimentin organization in OA chondrocytes. 
 
2. Materials and Methods 
2.1 Subjects 
Healthy articular cartilage (NoNo) was obtained from 12 donors (9 male, 3 female; ages 18-
72 years) within 24 h post-mortem. All donors had died as a result of trauma or a brief illness 
and none of them had been receiving corticosteroids or cytostatic drugs. OA affected cartilage 
was obtained from 14 patients (6 male, 8 female; ages 47-79 years) within 24 h from total 
knee arthroplasty. The cartilage from each of these patients was separated in visually intact 
cartilage (NoOA) and cartilage showing OA-lesions (OAOA). Figure 1 shows an image of a 
sample of NoOA and OAOA cartilage from the same patient, stained with indian ink, 
allowing fibrillated cartilage to be recognized [13]. The study was approved by the local 
Ethics Committee. 
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Figure 1: Image of articular cartilage stained with Indian ink. Both samples were isolated from the femur 
condyle from the same patient. On the upper slice (OAOA) the fibrillated surface is clearly visible. The lower 
slice (NoOA) shows a smooth, non-fibrillated surface. 
 
2.2 Isolation and culture of chondrocytes 
Human articular chondrocytes were isolated as previously described [14]. The  cartilage was 
diced into small fragments and chondrocytes were isolated by sequential enzymatic digestion 
(hyaluronidase, pronase, collagenase (Sigma-Aldrich, Steinheim, Germany)) as described in 
detail elsewhere [14]. Trypan blue exclusion revealed that >95% of the cells were viable after 
isolation. 
Chondrocyte cultures in alginate beads were prepared as described by Guo et al [15], with 
some modifications [16]. Briefly, chondrocytes suspended in 1 volume of double-
concentrated Hanks’ balanced salt solution (HBSS; Gibco, Grand Island, NY, USA) without 
calcium and magnesium, were carefully mixed with an equal volume of 2% alginate. The 
final chondrocyte concentration was 5 x 106 cells/ml. The chondrocyte-alginate suspension 
was slowly dripped through a 23-gauge needle into a 102 mM solution of calcium chloride 
and the beads were allowed to polymerize for 10 minutes at room temperature. Calcium 
chloride was removed and the beads were washed 3 times with 0,9 % sodium chloride.   
The beads were maintained in a 6-well plate (20 beads/well; ± 50.000 chondroctyes/bead) 
containing DMEM (Gibco) with 10% fetal calf serum, antibiotics and antimycotics (Gibco) 
and 50 µg/ml ascorbate in an incubator at 37°C and in 5% CO2. Medium was replaced three 
times a week for 10 days. 
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 2.3 Two-dimensional PAGE 
After the culture period, the medium was aspirated and the alginate beads were washed and 
dissolved by incubation in 55 mM tri-sodium citrate dihydrate pH 6.8, at room temperature. 
The resulting suspension was centrifuged at 1500 rpm for 10 min to separate cells with their 
CAM [17] from the constituents of the interterritorial matrix [5]. The resulting cell-pellet was 
washed three times with PBS. After washing and centrifugation, the chondrocytes were 
resuspended in Reagent 1 (40mM Tris) from the ReadyPrep Sequential Extraction Kit (Bio-
Rad, Hercules, CA, USA), containing protease inhibitors (Roche Diagnostics, Mannheim, 
Germany), a phosphatase inhibitor-cocktail (Sigma-Aldrich, Steinheim, Germany) and 
endonucleases (Sigma-Aldrich). Cells were lysed and the proteins were extracted using the 
ReadyPrep Sequential Extraction Kit (Bio-Rad) according to the manufacturer’s protocol with 
the exception that the second and third fraction were combined. This resulted in a soluble and 
hydrophobic protein fraction. Using this approach an increase in the total number of protein 
spots is detected and a more simplified protein pattern is achieved [18]. The soluble fraction is 
considered to be the representative of the cytosolic proteins and the hydrophobic fraction of 
the membrane-associated proteins. 
Two-dimensional electrophoresis (2-DE) was performed according to Tilleman et al. [19] 
with some minor modifications. The soluble fraction was desalted using ice-cold acetone 
precipitation. Proteins were dissolved in 300 µl of rehydration solution containing 7 M urea, 2 
M thiourea, 4% CHAPS, 0,2% carrier ampholyte solution and 12 µl/ml Destreak Reagent 
(Amersham Biosciences, Uppsala, Sweden). The hydrophobic fraction was diluted with an 
appropriate volume of the above rehydration buffer to achieve a final volume of 300 µl. 
Samples were applied to 17 cm non-linear pH 3-10 strips (Bio-Rad) and rehydrated overnight.  
Isoelectric focusing was performed for 100 kVh on the Protean Iso-Electrical-Focusing (IEF) 
cell (Bio-Rad).  After focusing, proteins were reduced and alkylated by incubating the strips 
for 15 min in 15 ml of equilibration buffer (6 M urea, 2 % (w/v) sodium-dodecyl-sulfate 
(SDS), 50 mM TrisHCl, 30% glycerol) containing 2% dithiothreitol (DTT) (w/v) for 
reduction and 4% (w/v) iodoacetamide for alkylation respectively. 
The strips were transferred onto vertical 12% (soluble fraction) and 10% (hydrophobic 
fraction) self-cast gels and fixed in place with 0,5% agarose. The second-dimensional gel 
electrophoresis was performed on a vertical Protean II xi Multi Cell (Bio-Rad) for 30 min at 
16mA/gel followed by 32 mA/gel for approximately 4.5 h at 10°C. 
The gels were sequentially stained with Pro-Q Diamond (Molecular Probes, Eugene, Oregon) 
according to the manufacturer’s protocol. PeppermintStick Phosphoprotein Molecular Weight 
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 Standards (Molecular Probes) were run beside the IEF-strip as positive and negative control 
for the Pro-Q Diamond stain.  The image was acquired using a VersaDoc imaging system 
(Bio-Rad) with UV-excitation and a 520 nm longpass emission filter. After detection of the 
phospho-image, gels were stained with Sypro Ruby (Bio-Rad) according to the 
manufacturer’s protocol. Proteins were detected using a VersaDoc with UV-excitation and a 
520 nm longpass emission filter.  
Sypro Ruby stained images were processed and analyzed using PDQuest software Version 
7.10 (Bio-Rad). Spots were detected using the spot detection wizard, background was 
removed by applying the floater background. Gels were matched to each other creating a 
match set standard image, which contains match information from all the individual gels. Spot 
intensities were normalized for total quantity in valid spots, in order to correct for small 
pipetting errors, minor staining differences, etc. This normalization strategy implies that the 
raw quantity of each spot is divided by the total quantity of all the spots in that gel that have 
been included in the master. Spots were considered as ‘significant differentially expressed’ if 
spot intensities were significant (p-value <0.05) different between the groups NoNo and 
NoOA or OAOA (Mann-Whitney U-test). The ‘NoOA’ and ‘OAOA’ groups were compared 
using Wilcoxon’s paired-sample test; p-values less than 0.05 were considered statistically 
significant. 
 
2.4 Sample preparation for MS analysis 
2D gel spots of interest were excised and transferred to micro-centrifuge tubes. The gel spots 
were washed twice (10 minutes/wash) with 200 µl of 25 mM ammonium bicarbonate/50% 
acetonitrile, dehydrated using acetonitrile until spots turn opaque and dried until complete 
dryness in a vacuum centrifuge. Proteins were digested with sequencing grade trypsin 
(Promega, Madison, WI., 10ng/µl in 25 mM ammonium bicarbonate) overnight at 37°C. 
Peptides were extracted twice using, 75µl of a 50% acetonitrile/5% trifluoroacetic acid 
solution, extracts of the same spot were pooled and dried in a vacuum centrifuge. 
 
2.5 Mass spectrometry and database analysis 
Peptides were resuspended using 0,1 % formic acid. For electrospray-ionization quadrupole 
time-of-flight (ESI Qq-Tof) analysis the resuspended peptides were injected on a Famos 
autosampler (LC Packings, Sunnyvale, CA, USA) and concentrated on a trap-column 
(PepMap, LC Packings) in buffer A (0,1% formic acid in water).  Peptides were separated on 
a C18 PepMap column (LC Packings) by a 45 min linear gradient from 6 to 100 % buffer B 
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 (80% acetonitrile and 0,1% formic acid in water).  The flow rate was 150 nl/min (Ultimate 
pump, LC Packings). 
ESI Qq-Tof analysis was performed on a Q-Tof I or a Q-Tof Ultima mass spectrometer 
(Waters, Milford USA), which was coupled to the LC-system via a nano-LC inlet. The 
instrument was calibrated using fragment ions generated from tandem mass-spectrometry 
(MS/MS) spectra of Glu-fibrinopeptide B (Sigma-Aldrich).  
Data processing and database searches against the Swiss-Prot database were performed using 
the Protein Lynx Global Server V.2.0 search engine (Waters) and via Mascot 
(http://www.matrixscience.com) or GPM X!3 algorithm (www.thegpm.org) after processing 
the MS/MS spectra using Mass Lynx v4.0. For an extended description of the protein 
identification parameters and the validation of the identifications, see supplementary data.  
 
2.6 Western Blot analysis 
Equal amounts (30 µg as determined by 2-D Quant kit, GE Healthcare, Fairfield, USA) of 
soluble fractions of 12 patients (4 NoNo, 4 NoOA and 4 OAOA) were loaded on 10% SDS-
PAGE gel. Equal loading was verified by Ponceau S staining (data not shown). MagicMark 
(Invitrogen, Paisley, UK) protein standards were run as molecular weight markers. 2-D gels 
were run as described above (soluble fraction from 2 NoNo samples and 2 OAOA samples), 
except that sample was applied to IPG-zoom strips (pH 4-7, Bio-Rad) and, after equilibration, 
strips were transferred to precast 10% SDS-PAGE Criterion gels (Bio-Rad). Strips were 
focused for 35 kVh and SDS-PAGE was performed at 200 V for approximately 1h. For one 
OAOA sample a second gel was run in parallel and Sypro Ruby stained, to allow spot picking 
and mass spectrometry analysis, as described above. Following 1-D and 2-D gel 
electrophoresis, proteins were transferred to nitrocellulose membranes (Bio-Rad). The 
resulting membranes were immunoblotted with anti-Vimentin MAb clone V9 (Sigma-
Aldrich), followed by anti-mouse HRP-conjugated Ab (Pierce, Rockford, IL, USA) and ECL 
chemiluminescence (Pierce). Chemiluminescence images were recorded using the VersaDoc-
imaging system (Bio-Rad). Densitometric analysis of the images was performed by Quantity 
One Software v 4.4.0 (Bio-Rad). 
 
2.7 Immunofluorescence microscopy 
Chondrocytes of cartilage samples of 2 additional healthy patients (NoNo) and 3 additional 
OA patients were isolated and cultured as described above. In one of the OA patients, no 
visually intact cartilage was present. Chondrocytes cultivated in alginate beads for 10 days 
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 were washed in PBS for 5 minutes. The medium used during sample processing was a 
modified Hanks Balanced Salt Solution (mHBSS) as described by Langelier et al. [20]. 
Chondrocytes were fixed in the alginate beads using 4 % para-formaldehyde (Sigma-Aldrich) 
for 15 minutes. Fixation was stopped by 3 washes in 100mM glycine. Alginate beads were 
smeared on poly-l-lysine coated glass slides. Specimens were permeabilized using Triton X-
100 (Sigma-Aldrich) 0,5%. Samples were washed and blocked using 5% Normal Goat Serum 
(NGS) for 1h and were incubated overnight at 4°C with primary mouse anti-vimentin clone 
V9 (Sigma-Aldrich) in 1% NGS in mHBSS. After three washes, they were incubated with 
anti-mouse AlexaFluor 488-conjugated secondary antibody (Molecular Probes) in 1% NGS, 
followed by phalloidin-TRITC (Sigma-Aldrich) staining for 1 h. Samples were washed three 
times and incubated in DAPI nuclear stain (Molecular Probes). Finally, glass slides were 
washed four times in mHBSS. The slides were mounted on a coverslip and samples were 
examined with confocal laser scanning microscopy (Bio-Rad MRC1024). At least 20, 
randomly selected, individual chondrocytes of each sample were imaged.  
 
3. Results 
3.1 Comparative proteome analysis of normal and OA chondrocytes 
We initiated this study by performing 2-DE, for both the soluble and hydrophobic fractions, 
on 20 samples (6 healthy (NoNo), 7 visually intact zones of cartilage from OA-patients 
(NoOA), 7 visually damaged zones of OA-cartilage (OAOA)). Extraction of the proteome 
from chondrocytes yielded an average cytosolic protein concentration of 2.39 ± 0.60 µg/µl 
and an average hydrophobic protein concentration of 1.94 ± 0.48 µg/µl. Gels were stained, 
scanned and digitized as described above. The match set’s standard images are shown in 
figure 2 and 3. In the samples of the soluble fraction 1301 ± 141 spots could be detected on 
each gel. In the hydrophobic fraction 1212 ± 96 spots (Sypro Ruby stain) could be detected. 
Spots which showed a significant (p<0.05) different intensity between NoNo versus NoOA or 
OAOA samples in Mann-Whitney U-test were considered as protein spots with a significant 
altered expression. The identified proteins are shown in table 1 and table 2, respectively. As 
NoOA and OAOA chondrocytes are isolated from the same knee joint, the corresponding spot 
intensities were compared using a Wilcoxon paired-sample test. This revealed 17 identified 
proteins which were differentially (p<0.05) expressed (table 3).  
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Figure 2: Match set’s standard image of 2-D 
separated proteins of the soluble fraction (derived 
from OAOA sample). Numbered spots are identified 
by mass spectrometry. 
 
Figure 3: Match set’s standard image of 2-D 
separated proteins of the hydrophobic fraction 
(derived from OAOA sample). Numbered spots are 
identified by mass spectrometry. 
 
Among the identified spots, several proteins are known to be involved in metabolic pathways 
(transaldolase, 6-phosphogluconolactonase, alpha-enolase and triose-phosphate isomerase and 
ATP-synthase (α-subunit)). Furthermore proteins related to apoptotic pathways (VDAC-
proteins and Annexins) and oxidative stress (Peroxiredoxin 6, Cu/Zn superoxide dismutase, 
Mn superoxide dismutase) were identified. 
Of special interest was the identification of two spots, both upregulated in OAOA, as 
vimentin (Figure 4). Both spots were located in the gel below the expected molecular weight 
of native vimentin (Figure 2), suggesting a more pronounced vimentin cleavage in OAOA.  
 
 
 
 
 
 
 
 
Figure 4: Two spots, identified as vimentin, showed a higher expression in OAOA samples. Bars represent 
relative average expression levels (± SEM) of spots 1404 and 1437 in each group. Black: NoNo, White: NoOA, 
Shaded: OAOA. 
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 Table 1: Identified protein spots, differentially expressed (p<0.05) between NoNo and NoOA samples. The 
Swiss-Prot accession number is mentioned between brackets. ‘SSP’ indicates the spot number (numbers 
followed by H refer to spots from hydrophobic fraction). ‘Phosphorylation’ indicates if spot was stained using 
Pro-Q Diamond. ‘ESI MS/MS’ indicates the number of peptide sequences obtained from ESI Q-TOF used for 
identification. ‘Ratio’ is the ratio of the average normalized spot intensity of the NoOA- to NoNo-group. 
Table 1A: Protein spots showing a higher expression in NoOA vs NoNo 
SSP Protein Phosphorylation ESI MS/MS Ratio 
0819 Glucosidase II beta subunit precursor (P14314) Yes 5 4.77 
2505 
Mannose-6-phosphate receptor binding protein 1 
(O60664) 
 4 2.98 
3501 H Stomatin-like protein 2 (Q9UJZ1)  3 2.59 
3714 Heat shock protein 70 kDa protein 1 (P08107)  2 2.28 
5602 H Protein disulfide isomerase A3 (P30101)  2 2.00 
6308 Annexin A1 (P04083)  5 4.95 
6515 Alpha enolase (P06733)  2 1.65 
7211 H Superoxide Dismutase Mn (P04179)  3 2.08 
8609 H ATP-synthase α-chain (P25705)  6 29.37 
Table 1B: Protein spots showing a lower expression in NoOA vs NoNo 
SSP Protein Phosphorylation ESI MS/MS Ratio 
1003 Divalent cation tolerant protein CUTA (O60888)  2 0.55 
1103 Calcyphosine (Q13938) Yes 3 0.44 
2112 Superoxide Dismutase Cu/Zn (P00441)  1 0.24 
4104 DJ-1 protein (Q99497)  2 0.49 
4218 Peroxiredoxin 6 (P30041)  6 0.59 
7006 Cystatin B (P04080)  2 0.45 
7014 Neddylin (Q15843)  2 0.49 
 
Table 2: Identified protein spots, differentially expressed (p<0.05) between NoNo and OAOA samples. The 
Swiss-Prot accession number is mentioned between brackets. ‘SSP’ indicates the spot number (numbers 
followed by H refer to spots from hydrophobic fraction). ‘Phosphorylation’ indicates if spot was stained using 
Pro-Q Diamond. ‘ESI MS/MS’ indicates the number of peptide sequences obtained from ESI Q-TOF used for 
identification. ‘Ratio’ is the ratio of the average normalized spot intensity of the OAOA- to NoNo-group. 
Table 2A: Protein spots showing a higher expression in OAOA vs NoNo 
SSP Protein Phosphorylation ESI MS/MS Ratio 
0819 Glucosidase II beta subunit precursor (P14314) Yes 5 2.47 
1404 Vimentin (P08670)  16 2.50 
1437 Vimentin (P08670) Yes 7 3.03 
2002 
Eukaryotic translation initiation factor 5A 
(P63241) 
 1 4.32 
3213 Beta-Hexosaminidase beta chain (P07686)  2 3.99 
3501 H Stomatin-like protein 2 (Q9UJZ1)  3 1.81 
3705 H Heat shock cognate 71 kDa protein (P11142)  7 1.62 
3714 Heat shock protein 70 kDa protein 1 (P08107)  2 2.52 
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 5602 H Protein disulfide isomerase A3 (P30101)  2 2.7 
6306 H 
Voltage-dependent anion-selective channel 
protein 2 (P45880) 
 2 1.86 
6308 Annexin A1 (P04083)  5 5.23 
6503 Alpha enolase (P06733)  3 1.5 
6515 Alpha enolase (P06733)  2 1.75 
6712 H Lamin A/C (P02545)  3 2.97 
7206 H Superoxide Dismutase Mn (P04179) Yes 3 1.76 
7211 H Superoxide Dismutase Mn (P04179)  3 2.91 
8212 
3-hydroxyacyl-CoA dehydrogenase type II 
(Q99714) 
 2 13.83 
8302 H 
Voltage-dependent anion-selective channel 
protein 1 (P21796) 
 3 1.65 
8609 H ATP-synthase α-chain (P25705)  6 52.97 
Table 2B: Protein spots showing a lower expression in OAOA vs NoNo 
SSP Protein Phosphorylation ESI MS/MS Ratio 
1003 Divalent cation tolerant protein CUTA (O60888)  2 0.65 
1103 Calcyphosine (Q13938) Yes 3 0.51 
2112 Superoxide Dismutase Cu/Zn (P00441)  1 0.42 
3104 Superoxide Dismutase Cu/Zn (P00441)  2 0.37 
4104 DJ-1 protein (Q99497)  2 0.57 
4218 Peroxiredoxin 6 (P30041)  6 0.38 
5005 Fatty acid-binding protein (P05413)  2 0.33 
7006 Cystatin B (P04080)  2 0.55 
7014 Neddylin (Q15843)  2 0.55 
 
Table 3: Identified protein spots, differentially expressed (p<0.05) between NoOA and OAOA samples. The 
Swiss-Prot accession number is mentioned between brackets. ‘SSP’ indicates the spot number (numbers 
followed by H refer to spots from hydrophobic fraction). ‘Phosphorylation’ indicates if spot was stained using 
Pro-Q Diamond. ‘ESI MS/MS’ indicates the number of peptide sequences obtained from ESI Q-TOF used for 
identification. ‘Ratio’ is the ratio of the average normalized spot intensity of the OAOA- to NoOA-group. 
Table 3A: Protein spots showing a higher expression in OAOA vs NoOA 
SSP Protein  Phosphorylation ESI MS/MS Ratio 
3012 S100 calcium-binding protein A4 (P26447)  2 2.11 
4205 6-phosphogluconolactonase (O95336)  2 1.84 
5116 Cofilin-1 (P23528) Yes 2 1.45 
5207 Protein-L-isoaspartate(D-aspartate) O-
methyltransferase (P22061) 
 3 1.62 
5214 Triosephosphate isomerase (P60174) Yes 3 1.88 
5307 Transaldolase (P37837)  2 3.19 
5409 H Annexin A1 (P04083)  3 1.43 
6712 H Lamin A/C (P02545)  3 1.44 
7202 H Superoxide Dismutase Mn (P04179)  2 1.21 
7211 H Superoxide Dismutase Mn (P04179)  3 1.40 
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 7316 Superoxide Dismutase Mn (P04179) Yes 4 3.15 
8212 3-hydroxyacyl-CoA dehydrogenase type II 
(Q99714) 
 2 3.27 
Table 3B: Protein spots showing a lower expression in OAOA vs NoOA 
SSP Protein  Phosphorylation  ESI MS/MS Ratio 
0012 S-100 calcium-binding protein A1(P23297) Yes 1 0.68 
0319 Acidic leucine-rich nuclear phosphoprotein 32 
family member B (Q92688) 
Yes 2 0.67 
0819 Glucosidase II beta subunit precursor (P14314) Yes 5 0.52 
1702 H  Golgi reassembly stacking protein 2 (Q9H8Y8)  2 0.60 
8404 H Annexin A2 (P07355)  2 0.31 
 
3.2 Several differentially expressed proteins were shown to be phosphorylated, using 
specific in-gel staining of phosphoproteins  
We next evaluated the phosphorylation status of differentially expressed proteins. Therefore, 
samples were sequentially stained with Pro-Q Diamond and Sypro Ruby. The Peppermint 
Stick Phosphoprotein Molecular Weight Standards showed the expected staining pattern for 
phosphorylated proteins, indicating the selectivity of the Pro-Q Diamond staining procedure 
(results not shown). In the samples of the soluble fraction 122 ± 15 spots could be detected on 
each gel, whereas in the hydrophobic fraction 96 ± 17 spots (ProQ-Diamond stain) could be 
detected. Spots showing a differential expression pattern in the comparative proteome 
analysis and which stained positive with Pro-Q Diamond are indicated as phosphoproteins in 
Tables 1, 2 and 3. Among these identified phosphorylated proteins, cofilin-1 is of special 
interest. Moreover, a known phosphorylation site at Ser-3 could be identified by mass 
spectrometry (supplementary data, figure 1). Cofilin is a key regulator of actin organisation as 
this protein is involved in severing and depolymerization of actin filaments (reviewed by 
DesMarais et al. [21]). As the activity of cofilin is inhibited by phosphorylation [22], the 
detected upregulation of this protein in OAOA chondrocytes will not necessarily result in a 
higher activity of this protein. Whether this had a biological impact on actin filaments was 
further investigated by immunofluorescence (see below).  
 
3.3 Vimentin cleavage was confirmed by western blot analysis 
As the data of the differential proteome analysis points to vimentin cleavage, vimentin and its 
cleavage products were investigated by 1-D gel electrophoresis and Western blotting, using a 
monoclonal antibody directed against a C-terminal amino-acid sequence of human vimentin. 
1-D Western blots clearly indicate the higher abundance of a band near 53 kDa, the molecular 
weight of native vimentin, in NoNo and NoOA samples compared to OAOA samples (Figure 
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 5). Moreover, a lower Mw band (near 43 kDa) of vimentin was found to be more intense in 3 
OAOA samples. A less intense staining of vimentin was observed in hydrophobic fractions, 
which showed less explicit differences between NoNo and NoOA/OAOA samples in the 53 
kDa region (supplementary data, figure 2).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5: 1-D Western blot analysis of the soluble fraction of 12 samples (from the left to the right: 4 NoNo 
samples, 4 NoOA samples and 4 OAOA samples). A: Equal amounts of soluble fractions of chondrocytes were 
loaded on 10% SDS-PAGE and immunoblotted. Immmunoblotting was performed using monoclonal anti-
vimentin (clone V9). Where NoNo and NoOA samples show a more intense band at the native molecular weight 
of vimentin (upper box), 3 OAOA samples show a more intense band near 43 kDa (lower box). B-C: Results of 
densitometric analysis. Bars represent relative average density (± SEM) of bands per group. Black: NoNo, 
White: NoOA, Shaded: OAOA. 
 
These findings confirmed the difference between NoNo and OAOA samples observed by 2-
DE. In addition, differences between the NoOA and OAOA group were observed. It should be 
noted however, that in the 2-DE analysis differences in vimentin spot intensities between 
NoOA and OAOA could not reach statistical significance, but showed p-values of 0,06 and 
0,08 for spot 1404 and 1437, respectively. Hence, it may be concluded that both the 1-D and 
2-D analysis, point to a higher abundance of low molecular weight vimentin in OAOA 
compared to NoNo and NoOA samples. To further characterize these bands, a 2-D Western 
blot was performed of 2 NoNo and 2 OAOA samples. All samples showed the same general 
trend: a decreased molecular weight between 53 kDa and 43 kDa was accompanied by a shift 
towards acidic pI (Figure 6). As the N-terminal sequence (78 amino acids) of native vimentin 
has a high pI (12.01 as computed by the pI/Mw tool at www.expasy.org), cleavage of this 
sequence will yield a protein with a theoretical pI of 4.71 and Mw of 45 kDa.  In contrast, 
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 cleavage of the amino acid sequence at the C-terminus, which yields a protein with a 
comparable Mw, resulted in a theoretical pI of 5.20. Both the lower pI-values of lower 
molecular weight fragments and the ability to detect the cleavage products with an antibody 
directed against a peptide located near the C-terminus, suggest that N-terminus of vimentin is 
cleaved. This hypothesis was further confirmed by mass spectrometry data. Sequence 
information about the different vimentin spots was obtained by mass spectrometry analysis of 
3 intense spots at different molecular weight (Figure 6). The matched peptides for the 
different spots are listed in table 4. Mass spectrometry data revealed that none of the matched 
peptides could be located near the N-terminus for the spots located at 48 kDa or below, while 
high sequence coverage was achieved for the sequence starting from amino acid 78. Peptides 
located near the N-terminus could be identified in the higher molecular weight spot. The 
combination of these data clearly points to N-terminal vimentin cleavage in OAOA. 
 
Figure 6: 2-D Western blot of the soluble 
fraction of OAOA sample. 30 µg of total 
protein was loaded on 4-7 IPG strip, 
transferred to 10% SDS-PAGE. Proteins 
were transferred to a nitrocellulose 
membrane and vimentin was detected using 
monoclonal anti-vimentin (clone V9). 1, 2 
and 3 indicate the protein spots that were 
excised from a gel, run in parallel to the gels 
used for Western blotting.  
 
 
Table 4: Results of the identification of 3 spots, identified as vimentin by Western blotting, at different 
molecular weight. Spots were excised from a gel run in parallel with the Western blots. Peptides, identified by 
ESI MS/MS, matched to the theoretical sequence are indicated in bold red. The indicated molecular weights are 
apparent molecular weights, as estimated by extrapolation of molecular weight markers.  
 
Matched peptides vimentin 3 (Mw: 53 kDa) 
     1 STRSVSSSSY RRMFGGPGTA SRPSSSRSYV TTSTRTYSLG SALRPSTSRS  
    51 LYASSPGGVY ATRSSAVRLR SSVPGVRLLQ DSVDFSLADA INTEFKNTRT  
   101 NEKVELQELN DRFANYIDKV RFLEQQNKIL LAELEQLKGQ GKSRLGDLYE  
   151 EEMRELRRQV DQLTNDKARV EVERDNLAED IMRLREKLQE EMLQREEAEN  
   201 TLQSFRQDVD NASLARLDLE RKVESLQEEI AFLKKLHEEE IQELQAQIQE  
   251 QHVQIDVDVS KPDLTAALRD VRQQYESVAA KNLQEAEEWY KSKFADLSEA  
   301 ANRNNDALRQ AKQESTEYRR QVQSLTCEVD ALKGTNESLE RQMREMEENF  
   351 AVEAANYQDT IGRLQDEIQN MKEEMARHLR EYQDLLNVKM ALDIEIATYR  
   401 KLLEGEESRI SLPLPNFSSL NLRETNLDSL PLVDTHSKRT LLIKTVETRD  
   451 GQVINETSQH HDDLE 
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3.4 Confocal microscopy of vimentin in chondrocytes points to disrupted vimentin 
organisation in OA 
As it is known that the amino-terminal domain is involved in the intermediate filament 
assembly [23] and in the interaction of vimentin with the plasma membrane [24], the detected 
N-terminal cleavage could possibly influence the organisation of vimentin in chondrocytes. 
Confocal microscopy studies were therefore performed on chondrocyte samples to test this 
hypothesis. The images show an altered distribution and organisation of vimentin in NoNo 
chondrocytes compared to OAOA chondrocytes. Representative images of each group are 
shown in figure 7. While the majority of NoNo chondrocytes clearly show a narrow intense 
pattern of vimentin expression confined to the cell membrane (figure 8), by contrast OAOA 
chondrocytes show a more diffuse distribution of fluorescence within the cytoplasm.  
As described above phosphorylated cofilin-1, an enzyme involved in actin filament 
organisation, was differentially expressed. To further elucidate the possible role of this 
enzyme in chondrocyte biology, actin filaments were stained using phalloidin-TRITC.  
Analysis of F-actin stained images did not reveal clear differences in F-actin organisation 
between the sample groups. 
 
 
 
Matched peptides vimentin 2 (Mw: 48 kDa) 
     1 STRSVSSSSY RRMFGGPGTA SRPSSSRSYV TTSTRTYSLG SALRPSTSRS  
    51 LYASSPGGVY ATRSSAVRLR SSVPGVRLLQ DSVDFSLADA INTEFKNTRT  
   101 NEKVELQELN DRFANYIDKV RFLEQQNKIL LAELEQLKGQ GKSRLGDLYE  
   151 EEMRELRRQV DQLTNDKARV EVERDNLAED IMRLREKLQE EMLQREEAEN  
   201 TLQSFRQDVD NASLARLDLE RKVESLQEEI AFLKKLHEEE IQELQAQIQE  
   251 QHVQIDVDVS KPDLTAALRD VRQQYESVAA KNLQEAEEWY KSKFADLSEA  
   301 ANRNNDALRQ AKQESTEYRR QVQSLTCEVD ALKGTNESLE RQMREMEENF  
   351 AVEAANYQDT IGRLQDEIQN MKEEMARHLR EYQDLLNVKM ALDIEIATYR  
   401 KLLEGEESRI SLPLPNFSSL NLRETNLDSL PLVDTHSKRT LLIKTVETRD  
   451 GQVINETSQH HDDLE 
 
Matched peptides vimentin 1 (Mw: 44 kDa) 
     1 STRSVSSSSY RRMFGGPGTA SRPSSSRSYV TTSTRTYSLG SALRPSTSRS  
    51 LYASSPGGVY ATRSSAVRLR SSVPGVRLLQ DSVDFSLADA INTEFKNTRT  
   101 NEKVELQELN DRFANYIDKV RFLEQQNKIL LAELEQLKGQ GKSRLGDLYE  
   151 EEMRELRRQV DQLTNDKARV EVERDNLAED IMRLREKLQE EMLQREEAEN  
   201 TLQSFRQDVD NASLARLDLE RKVESLQEEI AFLKKLHEEE IQELQAQIQE  
   251 QHVQIDVDVS KPDLTAALRD VRQQYESVAA KNLQEAEEWY KSKFADLSEA  
   301 ANRNNDALRQ AKQESTEYRR QVQSLTCEVD ALKGTNESLE RQMREMEENF  
   351 AVEAANYQDT IGRLQDEIQN MKEEMARHLR EYQDLLNVKM ALDIEIATYR  
   401 KLLEGEESRI SLPLPNFSSL NLRETNLDSL PLVDTHSKRT LLIKTVETRD  
   451 GQVINETSQH HDDLE 
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Figure 7: Representative confocal microscopy images of NoNo (upper panel), NoOA (middle panel) and OAOA 
chondrocytes (lower panel). Chondrocytes were immunostained for  vimentin (green), F-actin (red) and the 
nucleus (blue), shown as individual channels and in superposition from the left to the right. Scale bar indicates 5 
µm. Green panel (vimentin-staining): The majority of NoNo chondrocytes clearly show a narrow zone of 
fluorescence, in contrast to the spread fluorescence of OAOA chondrocytes. Red panel (F-actin staining): No 
clear differences in F-actin staining could be detected between the sample groups. All sample groups show a 
fluorescence signal distributed over the cytoplasm. Blue panel: nuclear DAPI-stain. Right panel: 
Superimposition of the three images. 
 
 
 
 
 
 
 
 
 
4. Discussion 
The goal of our study was to identify novel molecular mechanisms or proteins, participating 
and resulting in cartilage breakdown during the pathogenesis of OA. Therefore, we compared 
the protein expression patterns of chondrocytes obtained from intact cartilage (NoNo), from 
the visual intact zones (NoOA) and degenerated zones (OAOA) of OA-cartilage. 
Chondrocytes were cultured in alginate for 10 days. This culture system allows to selectively 
isolate the chondrocytes with their cell-associated matrix from the interterritorial matrix. In 
Figure 8: Percentage of chondrocytes showing a 
narrow intense zone of fluorescence at the periphery 
of the cytoplasm (expressed as mean ± SD). Cells 
were incubated with monoclonal anti-vimentin, 
followed by the appropriate secondary antibody, 
labelled in Alexa Fluor 488. 
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 alginate hydrogel, chondrocytes maintain their original phenotype and synthesize cartilage-
specific matrix components [25]. 
 
Interestingly, the NoOA group shows a different expression pattern for a substantial number 
of proteins in comparison to the NoNo group (see table 1), despite the fact that the 
chondrocytes are in both cases isolated from visually intact cartilage. These data confirm the 
hypothesis that chondrocytes undergo phenotypic alterations even before the development of 
visible cartilage damage [26]. 
 
Phenomena such as metabolic activation of OA chondrocytes in an attempt to repair cartilage 
breakdown [27], oxidative stress [28] and apoptotic processes [29] have previously been 
reported in the pathogenesis of osteoarthritis.  These phenomena are reflected in our analysis 
by the identification of proteins involved in these biological processes. Proteins involved in 
pentose-phosphate pathway (transaldolase and 6-phosphogluconolactonase), glycolysis 
(alpha-enolase and triose-phosphate isomerase) and oxidative phosphorylation (ATP-synthase 
(α-subunit)) were found to be upregulated in OA chondrocytes or in OAOA chondrocytes 
versus NoOA samples. The identification of several proteins involved in these pathways 
clearly points to a metabolic activation during OA, which is a known phenomenon. 
Furthermore, an increased role of oxidative phosphorylation in chondrocyte function under 
conditions of cartilage stress and increased energy demands, as might be associated with OA,  
has been suggested by Johnson et al [30].  
The differential expression of peroxiredoxin 6, an enzyme able to reduce hydroperoxides, 
Cu/Zn superoxide dismutase (Cu/ZnSOD) and Mn superoxide dismutase (MnSOD) illustrates 
the involvement of oxidative stress in the pathogenesis of OA. The biological role of 
Cu/ZnSOD and MnSOD, was previously reported in chondrocytes. In contrast the 
identification of peroxiredoxin 6, as a novel differentially expressed protein in OA, further 
contributes to the elucidation of oxidative stress pathways in the pathogenesis of OA. 
The role of apoptosis in OA is reflected by the identification of voltage-dependent anion 
channels (VDAC-1 and VDAC-2) and Annexin A1, which are proteins known to be involved 
in apoptotic processes [31] [32] [33]. The identification of VDAC-proteins, which have never 
been described in chondrocytes, can shed a new light on apoptotic processes in chondrocytes. 
 
The cytoskeletal architecture, which consists of a network of actin microfilaments, 
microtubules and intermediate filaments (IFs), plays a significant role in the physiology of 
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 chondrocytes. Furthermore, the cytoskeleton is important in biomechanics and is involved in 
mechanotransduction signalling pathways [34]. Vimentin IFs have been implicated in the 
mechanical integration of the cellular space [35]. In chondrocytes it has been suggested that 
the vimentin cytoskeleton could be implicated in mechanotransduction [20]. 2-D gel 
electrophoresis, mass spectrometry and Western blot data reveal a more pronounced N-
terminal cleavage of vimentin in OA. Since the amino-terminal domain of vimentin is 
involved in IF assembly [23] and in interaction of vimentin with the plasma membrane [24], 
we hypothesized that this vimentin cleavage would be reflected in an altered vimentin 
organisation in OA chondrocytes compared to healthy chondrocytes. This is confirmed by 
immunofluorescent labelling of vimentin in chondrocytes:  the more diffuse distribution of the 
fluorescent signal in OAOA chondrocytes over the cytoplasm, in contrast to intense 
fluorescence at the periphery in NoNo chondrocytes, probably reflects a disturbance in 
vimentin IF organisation and/or a diminished interaction of vimentin with the plasma 
membrane. Taken together, the combination of spot analysis data, 1-D and 2-D Western 
blotting, high sequence coverage mass spectrometry data and confocal microscopy images 
points indisputably to a disturbed vimentin organisation in OAOA chondrocytes. 
Trickey et al [36] demonstrated the possible involvement of vimentin IFs in the visco-elastic 
properties of human articular chondrocytes. Moreover, it has recently been shown that 
disassembly of the vimentin cytoskeleton, induced by acrylamide, disrupts chondrocyte 
homeostasis [37]. In consequence, the observed vimentin distortion probably plays a role in 
the pathogenesis of OA.   
Vimentin cleavage is a process which is described during apoptosis [38, 39]. Caspase-3 and 
caspase-8 are reported to be the proteases involved in apoptosis-related vimentin cleavage 
[40]. As a higher caspase-3 expression in OA-chondrocytes is documented [29], this enzyme 
is a candidate mediator for vimentin cleavage in OA. Nevertheless, the fragments, 
representing the most intense spots near 44 and 48 kDa, were investigated by mass 
spectrometry and contained the known cleavage site of caspase-3 and caspase-7 (AA 85) and 
caspase-6 and caspase-8 (AA 259) [40, 41]. This observation makes caspase-3 cleavage very 
unlikely. In addition, vimentin cleavage seems to be a phenomenon taking place in the basal 
metabolism of chondrocytes, since cleavage products were also detected in healthy samples. 
These findings allow us to suggest that caspase-mediated apoptotic processes are probably not 
involved in the observed vimentin cleavage. 
The primary cause of vimentin distortions remains unclear. It could be hypothesized that 
excessive mechanical load will induce an altered vimentin organisation, making vimentin 
83
 more susceptible to proteases. This hypothesis is supported by the suggestion of Durrant et al. 
[42] that chondrocytes modify their vimentin cytoskeleton in response to changing 
mechanical conditions. Alternatively, the observed vimentin alterations could be induced by 
imbalances in the autocrine and paracrine anabolic and catabolic pathways associated with 
OA. In OA chondrocytes the catabolic pathways override the anabolic pathways [26], which 
may result in OA-associated vimentin breakdown, possibly via downstream regulation of 
proteases or chaperone proteins. 
 
In conclusion, this study confirmed the metabolic activation of chondrocytes isolated from 
OA-cartilage and clearly demonstrated vimentin cytoskeleton disruption in OA-affected 
chondrocytes. These observations may shed new light on the pathogenesis of OA. Whether 
primary processes, involved in vimentin cleavage and cytoskeleton breakdown, are based on 
mechanical phenomena, on metabolic imbalances or on a combination of both will need 
further research.  
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Abstract 
Objective: αBcrystallin belongs to the family of small heat-shock proteins. This family of 
proteins is only poorly described in chondrocytes. We aimed to investigate the expression 
levels of αBcrystallin in chondrocytes isolated from healthy and osteoarthritis (OA)-affected 
patients. The functional role of this potentially interesting protein in chondrocyte metabolism 
was further explored using RNA-interference. 
Methods:  Western blot and real-time RT-PCR analysis were performed to confirm the 
differential expression of αBcrystallin between normal and OA chondrocytes cultured in 
alginate beads. Chondrocytes were stimulated with IL-1β and TNF-α to assess the influence 
of these cytokines on αBcrystallin protein expression. RNA-interference mediated gene 
knock-down was used to explore the role of this small heat shock protein in chondrocyte 
biology by transfecting low concentrations of siRNA in cultured chondrocytes. 
Results: We initially identified αBcrystallin as a differentially expressed small heat-shock 
protein between healthy and OA-affected chondrocytes. The decreased abundance of this 
protein in OA chondrocytes was confirmed by Western blot. Moreover, real-time RT-PCR 
confirmed the differential expression between chondrocytes isolated from visually intact and 
visually damaged zones of OA cartilage. The pro-inflammatory cytokines IL-1β and TNF-α, 
both down regulated αBcrystallin expression. Transfection of low concentrations siRNA in 
cultured chondrocytes resulted in an efficient knock down of αBcrystallin gene expression. 
This was accompanied by an altered expression of the chondrocyte specific genes BMP-2, 
aggrecan and collagen type II. 
Conclusion: This report identified the small heat shock protein αBcrystallin as a novel 
mediator of chondrocyte matrix gene expression that may contribute to the altered 
chondrocyte metabolism during the development of OA. 
 
 
 
 
 
 
 
 
92
1. Introduction 
αBcrystallin (HSPb5) belongs to the family of small heat shock proteins (sHSPs), which are a 
family of proteins with molecular weights below 30 kDa [1], whose function is to protect cells 
against stress factors. The expression of sHSPs may be induced by various stresses, such as 
heat-shock, oxidative stress and chemical stresses. These molecular chaperones have been 
implicated in many different cellular processes (reviewed in [2]). As chaperone proteins, 
sHSPs interact with several cytoskeletal elements. It has been shown that αBcrystallin 
interacts with the intermediate filaments during mitosis [3] and that intermediate filament 
actions can be altered by αBcrystallin [4]. In addition, this small heat-shock protein is 
involved in modulating the actin filament dynamics [5]. Kamradt et al described αBcrystallin 
as an inhibitor of TRAIL-induced apoptosis [6] and described it as a negative regulator of 
caspase-3 activation [7]. The expression of αBcrystallin decreased the level of reactive 
oxygen species (ROS) and abolished the burst of intracellular ROS induced by TNFα [8]. 
Furthermore, αBcrystallin has been related to cellular differentiation in several reports. Ito et 
al [9], described increasing levels of αBcrystallin during differentiation of C2C12 cells. 
Moreover, it has been shown that αBcrystallin expression was induced during the early stages 
of differentiation of the chondroprogenitor cell line ATDC5 [10]. Another small heat shock 
protein, HSP 25 (termed HSP 27 in human cells), has been shown to interfere with the 
differentiation of the C1 cell-line [11]. 
Based on its ability to interfere with diverse cellular events, it is not surprising that mutations 
in small heat shock protein genes are implicated in different diseases. For example, mutations 
in the αBcrystallin gene are associated with the neuromuscular disorder desmin-related 
myopathy [12] or with cataract [13]. Furthermore, this family of proteins have been related 
with cancer, Alzheimer, Parkinson and other neurodegenerative diseases (reviewed in [14]).  
 
Chondrocytes, the only resident cells in human articular cartilage, are generally considered to 
be key players in the cartilage degeneration associated with OA [15, 16]. The chondrocyte’s 
metabolism is influenced by a variety of cytokines and growth factors. Some are considered to 
be anabolic factors (IGF-I, TGF-β, BMPs), others are catabolic (IL-1, TNF-α). The balance 
between these anabolic and catabolic factors is of major importance to maintain a normal 
homeostasis in the chondrocyte’s metabolism. Until now, the knowledge of the processes 
involved in the pathogenesis of OA at the molecular level is limited. The disclosure of 
differentially expressed proteins and their subsequent study might help to better understand 
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events associated with the development of OA. This knowledge is crucial for the rational 
development of disease-modifying drugs.  
At present, little is known about small heat shock proteins in chondrocytes and articular 
cartilage and their potential role in the chondrocyte’s biology. Based on a differential 
proteome analysis [17], we compared the expression of αBcrystallin in samples of 
chondrocytes isolated from healthy and OA-cartilage. Furthermore, we investigated the effect 
of pro-inflammatory cytokines on the expression levels of this protein. The functional role of 
αBcrystallin in the chondrocyte’s biology was explored using RNA interference (RNAi): 
Knock down of the αBcrystallin gene expression by siRNA, revealed an altered expression of 
cartilage matrix genes. . 
 
2 Materials and Methods 
2.1 2-DE analysis 
In a proteomics screening study, protein extracts of chondrocytes (6 NoNo, 7 NoOA and 7 
OAOA samples) were analyzed by a 2-DE approach, as described in [17]. Briefly, soluble and 
hydrophobic fractions of protein extracts of chondrocytes were separated by 2-DE. Sypro 
Ruby stained gels were scanned and analyzed using PDQuest V 7.1. Statistically significant 
differentially expressed spots (p<0,05; Mann-Whitney U-test) were excised and subjected to 
tandem mass spectrometry for identification.  
 
2.2 Isolation of chondrocytes 
Human articular chondrocytes were isolated as previously described. Articular knee cartilage 
from donors without arthropathy (NoNo) (3 male, 2 female, mean age: 44 ± 25 years) was 
obtained within 24 h post-mortem. All donors had died as a result of trauma or a brief illness 
and none of them had been receiving corticosteroids or cytostatic drugs. OA affected cartilage 
was obtained from patients (6 male, 11 female, mean ages: 62 ± 11 years) within 24 h from 
total knee arthroplasty. The cartilage from each of these patients was separated in visually 
intact cartilage (NoOA) and cartilage showing OA-lesions (OAOA). This study was approved 
by the local Ethics Committee. The  cartilage obtained was diced into small fragments and 
chondrocytes were isolated by sequential enzymatic digestion (hyaluronidase, pronase, 
collagenase (Sigma-Aldrich, Steinheim, Germany)) as described in detail elsewhere [18]. 
Trypan blue exclusion revealed that >95% of the cells were viable after isolation. 
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2.3 Culture of chondrocytes in alginate gel 
Chondrocyte cultures in alginate beads were prepared as described by Guo et al [19], with 
some modifications [20]. The beads were maintained in a 6-well plate (20 beads/well; ± 
50.000 chondroctyes/bead) containing DMEM (Gibco) with 10% fetal calf serum, antibiotics 
and antimycotics (Gibco) in an incubator at 37°C and in 5% CO2. Medium was replaced three 
times a week for 10 days. After the culture period, the medium was aspirated and the alginate 
beads were washed and dissolved by incubation in 55 mM tri-sodium citrate dihydrate pH 6.8, 
at room temperature. The resulting suspension was centrifuged at 1500 rpm for 10 min to 
separate cells with their CAM from the constituents of the interterritorial matrix. The resulting 
cell-pellet was washed three times with PBS. 
 
2.4 Western Blot analysis 
Cell lysates of chondrocytes were prepared by resuspending cell pellets in 40mM Tris from 
the ReadyPrep Sequential Extraction Kit (Bio-Rad, Hercules, CA, USA), containing protease 
inhibitors (Roche Diagnostics, Mannheim, Germany) and a phosphatase inhibitor-cocktail 
(Sigma-Aldrich, Steinheim, Germany). Cells were lysed by sonication and the soluble 
proteins were isolated by centrifugation. Equal amounts (30 µg as determined by 2-D Quant 
kit, GE Healthcare, Fairfield, USA) of soluble fractions of 13 samples (5 NoNo, 4 NoOA and 
4 OAOA) were loaded on 10% SDS-PAGE gel. Equal loading was verified by Ponceau S 
staining (data not shown). MagicMark (Invitrogen, Paisley, UK) protein standards were run as 
molecular weight markers. Following 1-D gel electrophoresis, proteins were transferred to 
nitrocellulose membranes (Bio-Rad). The resulting membranes were immunostained with  
rabbit anti-αBcrystallin (FL-175) (Santa-Cruz, Biotechnology, Santa Cruz, USA) followed by 
an anti-rabbit HRP-conjugated secondary antibody (Pierce, Rockford, IL, USA) and ECL 
chemiluminescence detection (Supersignal West Dura Extended Duration Substrate, Pierce). 
Chemiluminescence images were recorded using the VersaDoc-imaging system (Bio-Rad). 
Image analysis was performed by Quantity One v 4.4.0 (Bio-Rad). 
2.5 Immunofluorescence microscopy 
Chondrocytes, cultured in alginate beads, were washed in PBS for 5 minutes. The medium 
used during sample processing was a modified Hanks Balanced Salt Solution (mHBSS). 
Chondrocytes were fixed in the alginate beads using 4 % para-formaldehyde (Sigma-Aldrich) 
for 15 minutes. Fixation was stopped by 3 washes in 100mM glycine. Alginate beads were 
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smeared on poly-l-lysine coated glass slides. Specimens were permeabilized using Triton X-
100 (Sigma-Aldrich) 0,5%. Samples were washed and blocked using 5% Normal Goat Serum 
(NGS) for 1h and were incubated overnight at 4°C with primary mouse monoclonal IgG1 anti-
αBcrystallin (Abcam, Cambridge, UK) in 1% NGS in mHBSS. After three washes, they were 
incubated with anti-mouse IgG1 AlexaFluor 488-conjugated secondary antibody (Molecular 
Probes) in 1% NGS for 1 h. Isotype controls were prepared and analyzed in parallel as 
negative controls. Samples were washed three times and incubated in DAPI nuclear stain 
(Molecular Probes). Finally, glass slides were washed four times in mHBSS. The slides were 
mounted on a coverslip and samples were examined with an AxioVert fluorescence 
microscope equipped with an ApoTome-module (Carl Zeiss). This allows to visualize cells in 
a near confocal-like way. At least 20, randomly selected, individual chondrocytes of the 
samples were imaged.  
 
2.6 Chondrocyte culture with pro-inflammatory cytokines 
Chondrocytes were isolated from 4 additional patients (2 male, 2 female) and cultured as 
described above for 7 days with IL-1β  (0,1 ng/ml; 0,5 ng/ml) or TNF-α (10 ng/ml). Each 
stimulation was performed in duplicate per patient. After the culture period cells were 
isolated, proteins extracted, separated and blotted as described above. 
 
2.7 Real-time PCR 
Chondrocytes from 6 patients (1 male, 5 female) were isolated and cultured as described 
above. After the culture period, Trizol (Invitrogen) was added to the isolated cells, and RNA 
was extracted according to the manufacturer’s instructions, followed by an additional 
purification step (RNeasy mini-kit (Qiagen)). This step included the digestion of DNA by 
deoxyribonuclease I (Invitrogen). cDNA was synthesized with oligo(dT) primers using the 
Superscript kit (Invitrogen).  
Real-time PCR was performed using the ABI 7000 Sequence Detection System (Applied 
Biosystems). Each reaction utilized 20 µl of iTaq Supermix with Rox (Bio-Rad, Hercules, 
CA) and 5 µl of cDNA and was performed in triplicate. The thermocycler conditions were 2 
min at 50°C, followed by 2 min at 95°C and 45 cycles, each at 95°C for 15 s and 60°C for 1 
min. Expression levels were normalized to those of human GAPDH, HPRT and PPIA. 
Relative quantization was calculated using the 2-∆∆Ct method [21, 22]. 
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2.8 RNAi 
Chondrocytes, isolated from visually intact cartilage of OA-patients, were cultured in alginate 
as described above. Experiments were performed on 4 different patient samples. After the 
culture period, cells were isolated and seeded in monolayer culture at a density of 50.000 
cells/cm2. Cells were transfected with 5nM siRNA (final concentration) directed against the 
αBcrystallin mRNA (Qiagen, Venlo, The Netherlands) or with a non-silencing control (All 
Stars Negative control siRNA, Qiagen), using HiPerfect transfection reagent (Qiagen). 
Separate transfections using siRNA directed against different sequences in the αBcrystallin 
mRNA strand have been performed. The transcript sequences targeted by the different siRNA 
sequences were: 5’- CAGGTTCTCTGTCAACCTGGA-3’ and 5’-
CTCCAGGGAGTTCCACAGGAA-3’. Cells were harvested at 48 hours and cDNA was 
synthesized as described above. Cell viability after transfection was at least 95% as 
determined by trypan blue exclusion. 
3 Results 
3.1 Differential proteome analysis of healthy and OA chondrocytes shows the 
differential expression of a protein identified as αBcrystallin 
In a previous study, a two-dimensional gel-based differential proteome analysis was 
performed [17]. Protein expression patterns of chondrocytes isolated from 7 healthy patients 
and 6 OA-patients were compared. This revealed the differential expression between normal 
and OA chondrocytes of a spot, which has now been identified as αBcrystallin (figure 1). 
This spot showed a down-regulation in OA samples (0,46 fold, p = 0,015) compared to 
healthy chondrocytes.  
 
3.2 Western blot analysis confirms differential abundance of αBcrystallin, a protein 
localized in the cytoplasm 
Expression levels of αBcrystallin were compared in lysates of chondrocytes isolated from 
healthy and OA-cartilage. Proteins extracted from chondrocytes isolated from healthy 
cartilage (NoNo, 5 patients) and visually intact NoOA and visually damaged (OAOA) OA-
cartilage (4 patients) were separated by 1-D gelelectrophoresis and electroblotted. Western 
blot analysis confirmed the higher abundance of αBcrystallin in NoNo samples. There was a 
gradual decrease in the abundance of αBcrystallin from NoNo, over NoOA, to OAOA 
samples. In addition, each individual OA-patient showed a higher intensity for αBcrystallin in 
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NoOA versus OAOA chondrocytes. The results of the densitometric analysis are shown in 
figure 2 (panel A and B). Western blots have been performed on albumin depleted synovial 
fluids of 3 OA, 3 RA and 3 SpA patients (up to 100 µg of protein was loaded on gel) and 
αBcrystallin could not be detected in these samples (results not shown).  
To determine the subcellular localization of αBcrystallin in chondrocytes, we performed 
immunofluorescence experiments. As shown in Figure 2C, αBcrystallin is prominently 
expressed in the cytoplasm. 
 
 
 
 
 
 
 
 
 
Figure 1: Representative zoom-image of the 2-DE gels of chondrocytes isolated from healthy cartilage (NoNo) 
and chondrocytes isolated from visually damaged zones of OA-cartilage (OAOA). The spot was reliably 
identified as αBcrystallin by tandem mass spectrometry: Observed: Indicates the observed m/z. Delta: Indicates 
the mass difference (Da) between the observed and the theoretical precursor ion mass; Miss: indicates the 
number of missed cleavage sites in a peptide; Score: Indicates the Mascot Ions Score; Expect: Indicates the 
expectation value for the peptide match; Peptide: indicates the identified peptide sequence in a 1-letter amino 
acid code. 
 
3.3 Real-time RT-PCR confirms the differential transcription of αBcrystallin at the 
mRNA level 
To evaluate whether the differential abundance of αBcrystallin is a consequence of a 
differential gene expression, mRNA levels for αBcrystallin were compared by real-time RT-
PCR in 6 additional paired samples of NoOA and OAOA chondrocytes. Consistent with the 
results at the protein level, the mRNA levels of αBcrystallin were upregulated in NoOA 
chondrocytes compared to OAOA chondrocytes in 5 of 6 samples analyzed (figure 2D).  
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Figure 2: Expression of αBcrystallin in human articular chondrocytes isolated from healthy and OA-cartilage. 
A: The protein levels of αBcrystallin in extracts of chondrocytes isolated from healthy cartilage (left 5 lanes) 
and from visually intact (middle 4 lanes) and visually damaged (right 4 lanes) OA-cartilage were determined by 
Western blot analysis. Equal loading was verified using Ponceau S (data not shown). A gradual decrease in 
expression could be detected from NoNo to OAOA chondrocytes. B: Results of the densitometric analysis of the 
Western blots, showing the mean expression (± SEM) in each group (relative to NoNo expression levels). *: 
Denotes statistical significance (p<0,05; Mann-Whitney U-test) compared to NoNo. C: Immunofluorescence 
microscopy images of OA chondrocytes. Upper image, green channel: monoclonal mouse IgG1 anti-αBcrystallin 
stained with AlexaFluor 488 labeled goat anti-mouse IgG1. Middle image, blue channel: DAPI nuclear stain. 
Lower image: Superimposition of green and blue channel. Scale bars indicate 10µm. D: Comparison of 
αBcrystallin expression at the mRNA level in chondrocytes isolated from 6 OA-patients. In 5 of 6 samples a 
marked reduction of αBcrystallin expression in OAOA samples was detected. mRNA levels were determined by 
quantitative real-time PCR. Expression levels have been calculated as the mean expression compared to 3 
different household genes (GAPDH, HPRT and PPIA). Different signs represent the relative expression of each 
individual patient, normalized to OAOA samples. 
 
3.4 The cytokines IL-1β and TNF-α suppress the expression of αBcrystallin 
It is known that pro-inflammatory cytokines such as IL-1β and TNF-α modulate the 
chondrocyte’s metabolism and may play an important role in OA-pathogenesis. To determine 
if the expression of αBcrystallin is influenced by pro-inflammatory cytokines, chondrocytes 
isolated from NoOA and OAOA samples were treated with IL-1β and TNF-α. In both cases, 
the pro-inflammatory cytokines suppressed the expression of αBcrystallin. Figure 3 shows the 
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dose-dependent suppression of αBcrystallin expression by IL-1β. No significant differences 
were found between NoOA and OAOA chondrocytes in response to 0,1 ng/ml IL-1β and 
TNF-α.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Relative expression of αBcrystallin as determined by Western blot. A: representative Western blot of 
chondrocytes isolated from NoOA-cartilage and stimulated with pro-inflammatory cytokines. From left to right: 
TNF-α (10 ng/ml); IL-1β (0.1 ng/ml); IL-1β (0,5 ng/ml); Unstimulated controls. Each stimulation was 
performed in duplicate. B-C: results of densitometric analysis. NoOA chondrocytes were isolated from 4 
patients and stimulated with IL-1β (0,1 ng/ml – 0,5 ng/ml) or TNF-α (10ng/ml); OAOA chondrocytes were 
stimulated with IL-1β (0,1 ng/ml) or TNF-α (10ng/ml). Each stimulation was performed in duplicate per patient. 
Bars represent the average of the relative expression of 4 patients ± SEM. Levels are normalized to unstimulated 
controls for NoOA and OAOA samples; * denotes statistical significance (p<0.05; Mann-Whitney U-test) 
compared to unstimulated controls. Black bars represent NoOA samples, white bars represent OAOA samples. 
 
3.5 RNAi induced knock-down of αBcrystallin expression by siRNA results in decreased 
expression of chondrocyte-specific markers 
A siRNA sequence against αBcrystallin (siCRYAB) was transfected in cultured 
chondrocytes. Non-silencing siRNA was used as a negative control. As shown in figure 4, 
siRNA transfection resulted in a marked reduction of αBcrystallin expression in CRYAB-
siRNA samples compared to negative controls. In parallel, a second sequence was transfected, 
showing similar results (data not shown). 
To explore the effects of a reduced expression of αBcrystallin on chondrocytes, the gene 
expression of 2 matrix genes (collagen type II and aggrecan) and the growth-factor, BMP-2, 
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was compared between silenced and non-silenced chondrocytes by real-time PCR. Figure 4 
shows the average expression ± SEM (4 experiments) of collagen type II, aggrecan and BMP-
2 in silenced and non-silenced samples. For the siCRYAB sequence, there is a marked 
reduction in gene expression for these genes compared to non-silenced controls. Samples 
transfected with the second sequence showed similar trends (data not shown). 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Expression levels of CRYAB, Aggrecan, BMP-2 and COL2A1 as determined by real-time PCR. 
Expression of CRYAB was suppressed by 21-mer siRNA sequences (siCRYAB). Non-silencing siRNA 
(Negative siControl) was used as a control.  Expression levels have been calculated as the mean expression 
compared to 3 different household genes (GAPDH, HPRT and PPIA) in 4 different patients, 48 hours after 
transfection. Bars represent the average relative expression ± SEM, normalized to Negative siControl. 
 
3.6 Morphologic dedifferentiation of chondrocytes is associated with a change in 
expression of αBcrystallin 
Based on the observation that a decreased expression of αBcrystallin is associated with a 
reduced expression of chondrocyte differentiation markers, further experiments were 
conducted to evaluate the expression of αBcrystallin in dedifferentiating cells. Chondrocytes 
isolated from 2 OA-patients were seeded in monolayer cultures at low density (30.000 
cells/cm2). As expected, this resulted in a quick morphologic change. Cell cultures were 
imaged at three different time points (Figure 5, upper panel) using a AxioVert 200 M (Carl 
Zeiss) microscope. At time of seeding, cells showed the typical rounded cell-shape associated 
with chondrocytes. After 144 hours almost all cells are attached to the surface and showed a 
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fibroblast-like morphology. Moreover, near confluent cell cultures were observed at this time 
point. The dedifferentiation was further confirmed by a strong decrease in the expression of 
BMP-2. This morphologic dedifferentiation is characterized by an initial decrease in 
expression of αBcrystallin. Between 72 and 144 hours, an increasing expression was 
observed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Discussion 
This report describes the differential expression of αBcrystallin in OA-affected chondrocytes. 
RNAi gene knock down of αBcrystallin, indicates a role for this small heat shock protein as a 
novel mediator of the gene expression of matrix genes in chondrocytes.  
The study was initiated by a gel-based proteome analysis, which revealed the differential 
abundance between healthy and OA chondrocytes of a protein, now identified as αBcrystallin. 
Subsequent Western blot analysis clearly showed the gradual decrease in abundance from 
normal to OA chondrocytes at the protein level. In addition to a differential abundance at the 
protein level, the mRNA levels of αBcrystallin are decreased in OAOA chondrocytes 
compared to NoOA chondrocytes, indicating that the differential expression is regulated at the 
Figure 5: Upper panel: Chondrocytes were 
seeded at low density. Cell cultures were imaged 
at different time points to allow visualization of 
morphologic dedifferentiation. From left to right: 
0 h, 72 h and 144 h. Scale bars represent 10µm. 
Lower panel: Relative expression of  αBcrystallin 
during dedifferentiation of chondrocytes seeded 
in monolayer at low density. Solid lines represent 
the expression of αBcrystallin at 0, 24, 48, 72 and 
144 hours, indicating an initial decreased 
expression during dedifferentiation. Dashed lines 
represent the expression of the differentiation 
marker BMP-2 at 0, 24, 48, 72 and 144 hours, 
confirming that the cells are dedifferentiating 
during the experiment. Expression levels of 
αBcrystallin and BMP-2 are average relative 
expression levels normalized to three household 
genes (GAPDH, HPRT, PPIA). ■: patient 1; 
▲patient 2. 
102
transcription level and is not a consequence of proteolytic cleavage or cellular translocation. It 
is known that αBcrystallin might translocate from the cytoplasm to the nucleus [23]. 
However, immunofluorescence microscopy data illustrate that αBcrystallin is mainly present 
in the cytoplasm of cultured chondrocytes.  
IL-1β and TNF-α are the most prominent catabolic cytokines, which are synthesized by the 
chondrocyte itself and are generally thought to be involved in OA-pathogenesis. Interestingly, 
the protein levels of αBcrystallin in chondrocytes are cytokine-dependent (figure 3). These 
data suggest that the observed differential expression of αBcrystallin between healthy and OA 
chondrocytes appears to be regulated by a cytokine-driven mechanism,. In consequence, 
αBcrystallin might be presented as a novel potential down-stream mediator of the effects of 
IL-1β and TNF-α on human articular chondrocytes. Further research will be needed to 
explore the relation between these cytokines and αBcrystallin and to unravel the importance 
of this relationship in the pathogenesis of OA. 
 
The differential expression of the CRYAB gene in OA chondrocytes and the sensitivity to 
inflammatory cytokines indicate a role for this gene as a potential mediator during the 
development of OA. This hypothesis is supported by a recent gene expression profiling study 
of articular cartilage in a rat model for early OA. The supplementary table of this report 
mentions a lower expression of CRYAB gene expression in rats with surgically induced OA 
compared to sham operated controls [24]. In addition, an αBcrystallin knockout model has 
been developed to study the role of this gene in lens structure and function [25]. Interestingly, 
the authors reported the display of a hunched posture in 12-month-old knockout mice which 
was associated with degenerative osteoarthritis of the intervertebral facet joints. Based on our 
own data, combined with the observations from the knockout model and the rat OA-model 
[24], a potential role in the pathophysiology of OA for this gene is very plausible.  
However, no data were available pointing to a relationship between αBcrystallin and 
processes involved in cartilage metabolism. To explore the potential role of αBcrystallin in 
the chondrocyte’s biology and to disclose the potential involvement in the pathogenesis of 
OA, we suppressed the expression of αBcrystallin by RNA interference (RNAi). RNAi is a 
naturally occurring phenomenon, which may be used to silence gene expression in 
mammalian cells by transfecting short double-stranded RNA sequences into the cells [26]. 
This results in a selective and efficient reduction in mRNA levels of the targeted gene 
(reviewed in [27]).  In this report, we used low concentrations of different siRNA sequences 
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(5 nM, final concentration), thereby largely avoiding the possibility of off-target effects [28]. 
Even with this low concentration of siRNA we were able to suppress the expression of 
αBcrystallin in an efficient and reproducible way. Hereby demonstrating the ability to achieve 
a sufficient knock-down with low quantities of siRNA in cells which synthesize an ECM, 
such as chondrocytes. Under the chosen experimental conditions, the resulting average knock-
down efficiency (50%) was comparable with the average reduction in mRNA expression 
between NoOA and OAOA samples (47%). This diminished expression was accompanied by 
a decreased expression in bone morphogenetic protein-2 (BMP-2) (figure 4), a member of the 
TGF-β superfamily. It has been shown that the expression of collagen type II (COL2A1) as 
well as aggrecan is induced by rhBMP-2 in alginate embedded chondrocytes [29]. Not 
surprisingly, the expression of the matrix genes aggrecan and collagen type II showed a 
similar trend as BMP-2 expression, in samples with a reduced αBcrystallin gene-expression. 
These findings further add to the evidence of the involvement of αBcrystallin in the 
chondrocyte’s biology.  
 
COL2A1 and BMP-2 have previously been reported as markers of a stable chondrocyte 
phenotype [30]. BMP-2 is known as a promoter of chondrogenic differentiation in multipotent 
mesenchymal cells [31]. Moreover, it is generally known that dedifferentiation of 
chondrocytes is associated with phenotypic alterations and a reduced expression of cartilage-
specific anabolic genes such as aggrecan and collagen type II [32]. Thus, the reduced 
expression of Aggrecan, COL2A1 and BMP-2 may reflect that a decreased expression of 
αBcrystallin drives the chondrocytes into a more dedifferentiated cell-type. This hypothesis is 
supported by the fact that αBcrystallin showed an initial decreased expression in 
dedifferentiating chondrocytes (figure 5). An inverse observation was made during the 
differentiation of the chondroprogenitor ATDC5 celline [10]: The differentiation of these cells 
into a chondrocyte-like phenotype, was associated with an initial increase in the expression of 
αBcrystallin. Furthermore, differential expression of αBcrystallin during differentiation 
processes has also been reported in C2C12 cells [9]. Our data and the data of Chen et al [10], 
implicate a potential role of αBcrystallin in the (de)differentiation processes of chondrocytes. 
Based hereon, it may be hypothesized that the increased expression of this gene in healthy 
chondrocytes may be associated with the differentiated and/or the rather metabolic inactive 
phenotype of healthy chondrocytes compared to the diseased counterparts.  
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In the RNAi-experiments, we used chondrocytes isolated from visually intact cartilage from 
OA-patients, which is more easily available than healthy articular cartilage. It is known that 
such chondrocytes show an altered phenotype compared to chondrocytes isolated from normal 
cartilage [33]. Whether the same relationship exists in healthy chondrocytes between 
αBcrystallin and chondrocyte-specific genes remains to be elucidated. Nevertheless, our 
experiments clearly indicate a functional link between αBcrystallin expression and 
chondrocyte-specific genes in OA-affected chondrocytes.  
 
In conclusion, our study clearly demonstrates the differential expression of αBcrystallin at 
different levels between healthy and OA-affected articular chondrocytes. This differential 
expression seems to be a consequence of a cytokine driven mechanism. Additionally, our data 
disclose αBcrystallin as a novel identified potential regulator of matrix gene expression. The 
association between reduced αBcrystallin levels and reduced levels of aggrecan, collagen type 
II and BMP-2, further adds to the evidence that this protein might be involved in phenotypic 
changes of chondrocytes during the development of OA.  
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 Abstract 
Objective: In recent years, some studies have been initiated to disclose the proteome of human 
chondrocytes and cartilage. Despite these studies, comprehensive information of the 
chondrocyte proteome remains limited. Especially the membrane and low-abundance 
proteome remain largely unknown. This study aims to dig further in the proteome expressed 
by human knee chondrocytes, thereby providing a database for future biomolecular research. 
Methods: Chondrocytes isolated from human knee cartilage samples were cultured in a three-
dimensional alginate culture system. To simplify the protein mixtures, proteins extracted from 
chondrocyte cell lysates were fractionated based on hydrophobicity and molecular weight. 
Proteins were digested and the resulting peptides were separated and identified by an on-line 
2-D nanoLC system coupled to a Qq-TOF mass spectrometer.   
Results: Using extensive prefractionation, several membrane proteins, transcription factors 
and other low-abundance proteins could be identified. Moreover, low molecular weight 
proteins, generally lost in a gel-based approach, could be enriched and identified. Several 
proteins, known to play an important role in chondrocyte homeostasis and OA-pathogenesis, 
such as tissue inhibitors of matrix metalloproteinases and IGF-binding proteins could be 
reliably identified. On the other hand, proteins which are related to cytokine/growth factor 
pathways and which have never been described in chondrocytes could be detected. In 
addition, novel proteins related to known disease pathways or disease processes were 
disclosed. The aim of the chondrocyte proteome database was illustrated by the rational 
selection of HSP27, a protein related to the previously described αBcrystallin, for further 
differential expression analysis. 
Conclusion: Extensive prefractionation of proteins followed by 2-D nanoLC coupled to mass 
spectrometry allows to dig deeper in the chondrocyte proteome. This study is a first 
exploration of the ‘hidden’ proteome of articular chondrocytes and may serve as a reference 
tool for future biomolecular research. 
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 1. Introduction 
Osteoarthritis (OA) has become one of the major health problems in the western world [1]. 
The key hallmark of this disease is a slow progressive degeneration of the articular cartilage 
[2]. Articular cartilage forms a specialized, smooth connective tissue that is weight bearing 
and that serves as a gliding surface allowing a lithe movement of the joints. Cartilage is a very 
attractive tissue as it contains only one single cell type. However, for proteomics studies this 
forms a major challenge, as this cell type comprises only 1% of the cartilage volume and the 
majority of the tissue is formed by highly abundant extracellular-matrix (ECM) components 
[3]. As it is generally accepted that disturbances in chondrocyte metabolism are involved in 
the pathogenesis of OA [4], the knowledge of the chondrocyte- as well as the cartilage-
proteome may provide a new tool, which may assist in the elucidation of pathways involved 
in cartilage destruction associated with OA. 
In recent years, several attempts have been performed to tackle the chondrocyte and/or 
cartilage proteomes. An extensive prefractionation method followed by 2-DE gel separation 
was proposed by Vincourt et al [5]. A limited number of unique proteins were identified by 
MALDI-TOF mass spectrometry of gel-separated spots. A 1-D SDS-PAGE approach 
combined with tandem mass spectrometry, resulted in the identification of 100 different 
proteins from knee cartilage specimens [6]. A 2-DE based approach was used to identify 
proteins of monolayer cultured human articular chondrocytes by Ruiz-Romero et al. [7], 
yielding a set of 93 unique proteins. In a subsequent study, the same group initiated the 
proteome characterization of mitochondria of chondrocytes, resulting in the identification of 
49 unique proteins [8]. Despite these studies, there is some lack of comprehensive information 
from cartilage tissue as well as isolated chondrocytes. More specific, the ‘hidden’ proteome 
which is not accessible by standard 2-DE methods, is poorly characterized. 
Prefractionation based on hydrophobicity is a well known sample preparation method in 2-D 
gel applications to achieve more simplified spot patterns [9]. Whereas 2-DE remains very 
attractive for differential expression analysis [10], 2-D LC methods have become the method 
of choice for the large-scale characterization of a given proteome. In this study, we combine 
such 2-D LC MS-approach with prefractionation methods to dig deeper in the proteome of 
human chondrocytes.  
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 2. Materials and Methods 
2.1 Isolation and culture of chondrocytes 
Human articular knee cartilage was obtained from 4 donors (one male, three female, median 
age ± SD: 70 ± 10,9 years) after total knee arthroplasty. The study protocol was approved by 
the local Ethics Committee. The  cartilage was diced into small fragments and chondrocytes 
were isolated by sequential enzymatic digestion (hyaluronidase, pronase, collagenase (Sigma-
Aldrich, Steinheim, Germany)) as described in detail elsewhere [11]. Trypan blue exclusion 
revealed that >95% of the cells were viable after isolation. 
Chondrocyte cultures in alginate beads were prepared and maintained as described previously 
[12]. For each sample, 15-17,5 x 106 chondrocytes were lysed and treated as described below. 
 
2.2 Sample preparation and protein digestion 
Total cell lysate- Isolated chondrocytes were resuspended and lysed in a denaturing buffer 
containing 8 M urea. After reduction and alkylation, proteins were digested with sequencing 
grade trypsin at 37°C for 12 to 16 h. Peptide solutions were desalted using solid-phase 
extraction cartridges (Oasis®, Waters, Milford, USA), dried in a vacuum-centrifuge and 
frozen at -80°C until use. 
Fractionation based on hydrophobicity and Mw- Isolated chondrocytes were resuspended in 
Reagent 1 (40mM Tris) from the ReadyPrep Sequential Extraction Kit (Bio-Rad, Hercules, 
CA, USA), containing protease inhibitors (Roche Diagnostics, Mannheim, Germany) and a 
phosphatase inhibitor-cocktail (Sigma-Aldrich, Steinheim, Germany). Cells were lysed by 
sonication and the proteins were extracted using the ReadyPrep Sequential Extraction Kit 
(Bio-Rad) according to the manufacturer’s protocol. This resulted in a soluble, an 
intermediate and a hydrophobic protein fraction [9]. All fractions were dialysed using 2 kDa 
Mw cut-off centrifugal devices (Vivaspin, Vivascience). The resulting concentrates were 
diluted in dissolution buffer (iTRAQ reagents kit, Applied Biosystems) supplemented with a 
SDS-containing denaturant solution. After reduction and alkylation, the intermediate and 
hydrophobic fractions were digested using sequencing grade trypsin. The soluble fraction was 
further fractionated, based on molecular weight using 300 kDa, 100 kDa, 10 kDa and 2 kDa 
Mw cut-off centrifugal devices (Vivaspin, Vivascience). Each resulting concentrate was 
digested as described above. For a second chondrocyte sample, the resulting pellet after the 
second extraction, was resuspended in a 2% SDS-solution containing 5% β-mercaptoethanol. 
The suspension was heated at 95°C for 5 minutes. The sample was cooled to room 
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 temperature and centrifuged at 15000 rpm. The resulting supernatans was subjected to 1-D 
gelelectrophoresis. Precision Plus All Blue standards (Bio-Rad) were run in parallel as 
molecular weight markers. The gel was stained with Colloidal Coomassie blue (Pierce). The 
lane was divided in eight zones and each zone was isolated and cut in smaller fragments 
followed by in-gel digestion as described previously [12], except that larger volumes were 
used. 
 
2.3 On-line two-dimensional nanoLC-MS 
Peptides were resuspended in buffer A (Buffer A: 2,5 mM NaH2PO4, 3% ACN, pH=2,7). For 
ESI Qq-Tof analysis the resuspended peptides were injected on an Ultimate 3000 autosampler 
(LC Packings, Sunnyvale, CA, USA) and trapped on a Poros 10S strong-cation exchange 
(SCX) column (300 µm i.d. x 15 cm). Peptides were eluted from the SCX column by a 840 
min discontinuous gradient from 0 to 100 % buffer B (Buffer B: 2,5 mM NaH2PO4, 500 mM 
NaCl, 3% ACN, pH=2,7, flow rate= 6 µl/min).  Two reversed-phase trap-columns (PepMap, 
LC Packings) were used for parallel trapping of the peptides, eluting from the SCX column, 
prior to the separation on a C18 PepMap column (LC Packings) by a 70 min linear gradient 
from 6 to 100 % buffer C (80% acetonitrile and 0,1% formic acid in water). A Switchos pump 
(LC Packings) [pumping 12 µl/min buffer D (0,1% formic acid in water)] was coupled to the 
LC-system to wash the trap columns prior to peptide elution. ESI Qq-Tof analysis was 
performed on a Q-Tof Ultima mass spectrometer (Waters, Milford USA), which was coupled 
to the LC-system via a nano-LC inlet. The instrument was calibrated using fragment ions 
generated from MS/MS of Glu-fibrinopeptide B (Sigma-Aldrich).  
 
2.4 Database searching 
The Q-TOF was operated in a data-dependent mode by performing MS/MS scans for the 7 the 
most intense peaks from each MS scan. The MS scan range was 450-1100 m/z. Peak list files 
were generated from the raw data by Mascot Distiller version 2.1.0.0 (Matrix Science). The 
generated files were merged into a single .mgf file. Database searches against the Swiss-Prot 
database (version 51.6) were performed using an in-house licensed Mascot search engine 
(version 2.2.0.0). The search parameters were: a maximum of 1 missed cleavages using 
trypsin; fixed modifications were carbamidomethylation and variable modifications were 
oxidation of methionine and N-terminal acetylation; the mass tolerances were set to 0.20 and 
0.15 Da for precursor ions and fragment ions respectively; one C13 was allowed. Only protein 
identifications with a p-value less than 0,01 were accepted. Protein identifications based on a 
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 single peptide hit were manually validated and only accepted if three consecutive y or b ions 
matched intense peaks in the MS/MS-spectrum.  
 
2.5 Western Blot analysis 
Chondrocyte samples of 6 healthy donors (4 male, 2 female, median age ± SD: 46,5 ± 23,6 
years) and 6 OA patients (3 male, 3 female, median age ± SD: 66,5 ± 11,1 years) were 
collected, isolated and cultured as described previously [13]. Cell lysates of chondrocytes 
were prepared by resuspending cell pellets in 40mM Tris from the ReadyPrep Sequential 
Extraction Kit (Bio-Rad, Hercules, CA, USA), containing protease inhibitors (Roche 
Diagnostics, Mannheim, Germany) and a phosphatase inhibitor-cocktail (Sigma-Aldrich, 
Steinheim, Germany). Cells were lysed by sonication and the soluble proteins were isolated 
by centrifugation. Equal amounts (30 µg as determined by 2-D Quant kit, GE Healthcare, 
Fairfield, USA) of soluble fractions of 18 samples [6 NoNo (chondrocytes isolated from 
healthy cartilage), 6 NoOA (chondrocytes isolated from visually intact cartilage of OA-
patients) and 6 OAOA (chondrocytes isolated from visually damaged zones of OA-cartilage)] 
were loaded on 10% SDS-PAGE gels. Equal loading was verified by Ponceau S staining (data 
not shown). MagicMark (Invitrogen, Paisley, UK) protein standards were run as molecular 
weight markers. Following 1-D gel electrophoresis, proteins were transferred to nitrocellulose 
membranes (Bio-Rad). The resulting membranes were immunostained with a mouse 
monoclonal anti-HSP27 (G3.1) (Abcam, Cambridge, UK) followed by an anti-mouse HRP-
conjugated secondary antibody (Pierce, Rockford, IL, USA) and enhanced 
chemilumineschence detection (Supersignal West Dura Extended Duration Substrate, Pierce). 
Chemiluminescence images were recorded using the VersaDoc-imaging system (Bio-Rad). 
Image analysis was performed by Quantity One v 4.4.0 (Bio-Rad). 
 
3. Results and Discussion 
Prefractionation based on hydrophobicity and molecular weight yields a higher number of 
identifications 
Fractionation based on hydrophobicity is a well-known method to simplify spot patterns in a 
2-DE based proteomics approach [9]. In this study, such approach was used as 
prefractionation tool to explore the chondrocyte proteome. In the unfractionated samples, 379 
unique proteins could be identified. Using prefractionation based on the hydrophobicity and 
the molecular weight of the proteins this number was extended to 717. As could be expected, 
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prefractionation based on hydrophobicity results in the enrichment of membrane proteins in 
the hydrophobic fractions. Whereas 40,6 % of the identified proteins were annotated to the 
membrane (as assigned by the GeneOntology database, www.geneontology.org) in the 
hydrophobic fractions, this was only 22,6 % in the soluble fractions.  
Next to hydrophobicity, the molecular weight of the proteins was used as a second 
prefractionation tool. Low molecular weight proteins might be expected to be 
underrepresented in a shotgun proteomics approach, given the fact that a lower number of 
identifiable peptides per protein are generated. To increase the number of protein 
identifications with a low molecular weight, we combined the sequential extraction with 
prefractionation of the soluble proteome by ultrafiltration. The four resulting fractions 
(theoretical Mw-ranges: 2-10, 10-100, 100-300, >300 kDa) were analysed separately by LC-
MS. Figure 1 indicates an enrichment of low molecular weight proteins (<15 kDa) in the 2-10 
kDa fraction. However, in this fraction a considerable number of identified proteins had a 
theoretical molecular weight which is higher than the predicted cut-off. It may be assumed 
that, next to the nature of filtration membranes, phenomena such as protein post-translational 
modifications will also contribute to this observation.  
 
 
 
 
 
 
 
 
 
Figure 1: % of protein identifications which show a theoretical molecular weight (molecular weight of the 
unprocessed precursor) smaller than 15 kDa. The soluble proteome was fractionated based on ultrafiltration in 
four different fractions: 2-10 kDa, 10-100 kDa, 100-300 kDa, >300 kDa, resulting in an enrichment of low 
molecular weight proteins. Bars indicate mean % ± SD. 
 
2-D nanoLC combined with tandem MS yields a “chondrocyte proteome database” 
The aim of this study was to provide a database which may assist in future molecular biology 
research in chondrocytes. Using extensive prefractionation followed by ESI-MS/MS, 779 
unique proteins expressed by cultured chondrocytes could be reliably (p<0,01) identified. The 
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 Cytoplasm: 556Membrane: 203
Nucleus: 129
Extracellular: 73
Unknown: 24
false discovery rate was estimated at 0,3 % by searching a reversed database. The complete 
list of identifications and the corresponding experimental data can be found in the 
supplementary table.  
 
 
 
 
 
 
 
 
 
 
 
The cellular localization of the identified proteins was assigned by searching the 
GeneOntology database, indicating a diverse distribution of the identified proteins (see figure 
2). 556 of the identified proteins are localized in the cytoplasm, 203 proteins were annotated 
to the membrane, 129 proteins to the nucleus and 73 are located in the extracellular 
environment. A gene ontology search on the molecular function indicated that 22 identified 
proteins are involved in signal transduction, whereas 7 proteins were identified with 
transcription factor activity. 14 proteins were identified with receptor activity and 32 
transmembrane transporters were reported (see Table 1). 
 
Several proteins have been identified, which are known to play an important role in 
chondrocyte homeostasis and OA-pathogenesis. For example, insulin-like growth factor 
binding proteins (IGFBP-7), tissue inhibitors of matrix metalloproteinases (TIMP-1) and 
matrix-metalloproteinases (MMP-3 and MMP-1).  
Alternatively, several extracellular matrix proteins and proteins involved in ECM organization 
(such as the CD-44 receptor and β1- and β5-integrin) could be identified. As could be 
expected from chondrocytes cultured in alginate beads, collagens type I, II and VI were 
identified next to other well known matrix proteins among these the aggrecan core protein, 
biglycan, perlecan, the hyaluronan and proteoglycan link protein and chondroitin sulphate 
proteoglycan 4 precursor. The three different α chains which form the heterotrimer type VI 
Figure 1: Pie chart showing the 
cellular localization of the 
identified proteins, as assigned by 
the GeneOntology database. 
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 collagen could all be identified with high sequence coverage (α1: 35%, α2: 26%, α3: 25%) 
indicating a relatively high abundance especially if compared to collagen type II (1% 
sequence coverage). However, it is known that type VI collagen forms only a small portion of 
the cartilage collagens [14]. This clearly indicates that during cell isolation after alginate 
culture the chondrocytes are selectively isolated with their cell-associated matrix from the 
interterritorial matrix, as the pericellular matrix is rich in type VI collagen and excludes type 
II collagen [15].    
 
 
Table 1: Protein identifications which were assigned to the following GeneOntlogy-terms: transmembrane 
transporter activity, kinase activity, signal transducer activity, structural constituent of cytoskeleton, extracellular 
matrix structural constituent, receptor activity, antioxidant activity, transcription factor activity, transmembrane 
receptor activity. 
Transmembrane 
transporter activity 
ADT1_HUMAN, ADT3_HUMAN, ANKH_HUMAN, 
ANXA7_HUMAN, AT1A1_HUMAN, ATOX1_HUMAN, 
ATPA_HUMAN, ATPB_HUMAN, ATPD_HUMAN, 
ATPK_HUMAN, ATPO_HUMAN, CERU_HUMAN, 
CLIC1_HUMAN, CLIC4_HUMAN, COX2_HUMAN, 
CX6B1_HUMAN, FRDA_HUMAN, KE4_HUMAN, 
MPCP_HUMAN, PEA15_HUMAN, S29A1_HUMAN, 
SC61G_HUMAN, TOM40_HUMAN, TTHY_HUMAN, 
TXTP_HUMAN, UCRH_HUMAN, UQCR1_HUMAN, 
VATB1_HUMAN, VATG1_HUMAN, VDAC1_HUMAN, 
VDAC2_HUMAN, VDAC3_HUMAN 
Kinase activity 
DAK_HUMAN, FRDA_HUMAN, HXK1_HUMAN, ILK_HUMAN, 
K6PL_HUMAN, K6PP_HUMAN, KAD1_HUMAN, 
KAD2_HUMAN, KAD3_HUMAN, KAPCA_HUMAN, 
KCRB_HUMAN, KCY_HUMAN, KPYM_HUMAN, 
NDKA_HUMAN, NDKB_HUMAN, PAPS1_HUMAN, 
PAPS2_HUMAN, PASK_HUMAN, PDXK_HUMAN, 
PGK1_HUMAN, PGK2_HUMAN, RBSK_HUMAN 
Signal transducer activity 
ARF1_HUMAN, CSPG4_HUMAN, EF1D_HUMAN, 
FLNA_HUMAN, GBB1_HUMAN, GNA12_HUMAN, 
GNAL_HUMAN, GRB2_HUMAN, HMOX1_HUMAN, 
IFM1_HUMAN, LEG1_HUMAN, PASK_HUMAN, 
PLCD1_HUMAN, RHG01_HUMAN, RHOA_HUMAN, 
RHOC_HUMAN, SAM68_HUMAN, SH3L1_HUMAN, 
STAT1_HUMAN, TSP1_HUMAN, VAPA_HUMAN 
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 Structural constituent of 
cytoskeleton 
ACTB_HUMAN, ACTG_HUMAN, ARC1B_HUMAN, 
E41L2_HUMAN, K1C16_HUMAN, K1C9_HUMAN, 
K22E_HUMAN, K2C1_HUMAN, MOES_HUMAN, 
PLEC1_HUMAN, SPTA2_HUMAN, SPTB2_HUMAN, 
TBB2A_HUMAN, TBB3_HUMAN, TLN1_HUMAN, 
VIME_HUMAN 
Extracellular matrix 
structural constituent 
CH3L1_HUMAN, CHAD_HUMAN, CO1A1_HUMAN, 
CO1A2_HUMAN, CO2A1_HUMAN, CO6A1_HUMAN, 
CO6A2_HUMAN, COMP_HUMAN, FINC_HUMAN, 
MGP_HUMAN, PGCA_HUMAN, PGS1_HUMAN, 
PRELP_HUMAN, RRBP1_HUMAN 
Receptor activity 
AMRP_HUMAN, CD44_HUMAN, FKB1A_HUMAN, 
ICAM1_HUMAN, ITB1_HUMAN, ITB5_HUMAN, K2C1_HUMAN, 
LRP1_HUMAN, MEP50_HUMAN, MRC2_HUMAN, 
NPC1_HUMAN, RRBP1_HUMAN, RSSA_HUMAN, 
SCRB2_HUMAN, TBB3_HUMAN, TMED7_HUMAN 
Antioxidant activity 
APOE_HUMAN, GPX1_HUMAN, PRDX1_HUMAN, 
PRDX2_HUMAN, PRDX3_HUMAN, PRDX4_HUMAN, 
PRDX5_HUMAN, PRDX6_HUMAN, SODC_HUMAN 
Transcription factor 
activity 
ENOA_HUMAN, HMGA1_HUMAN, HMGB2_HUMAN, 
NDKB_HUMAN, PA2G4_HUMAN, STAT1_HUMAN, 
YBOX1_HUMAN 
Transmembrane receptor 
activity 
AMRP_HUMAN, ICAM1_HUMAN, NPC1_HUMAN, 
RSSA_HUMAN 
 
Oxygen and reactive oxygen species (ROS) play a crucial role in the control of cartilage 
homeostasis and oxidative stress has previously been related to the pathogenesis of OA 
(reviewed in [16]). Gene ontology searches showed the identification of 10 proteins with anti-
oxidant activity, among these the peroxredoxins. Peroxiredoxins are a family of proteins 
involved in oxidative stress defence in human cells. In previous studies peroxiredoxin-5 [17] 
and -6 [13] have been reported as differentially expressed proteins in OA-affected 
chondrocytes. Our data show the reliable identification of the other members of the 
peroxiredoxin-family (PRDX1, 2, 3 and 4). Given the reported differential expression of 
peroxiredoxin-5 and -6, this protein family absolutely merits further investigation. 
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 Rational target selection from the database may provide novel potential players in OA-
pathogenesis 
In a previous report we identified αBcrystallin as a potential interesting protein in OA 
pathogenesis (Chapter III, Part 2). αBcrystallin belongs to the family of small heat-shock 
proteins (sHSPs), a family of molecular chaperones with similar structures and functionalities 
[18]. Until now, 10 different sHSPs have been identified in human [19]. In our study, we 
identified three members of this family: the previously described αBcrystallin (HSPb5), 
HSP20 (HSPb6) and HSP27 (HSPb1). HSP27 and αBcrystallin are the most investigated 
sHSPs. Both are very closely related, in function as well as in structure (reviewed in [20]).  
Based hereon, we further examined the expression of HSP27 in OA-affected chondrocytes, 
revealing a reduced expression of this protein in cultured OA-chondrocytes. Our western blot 
data show a significant reduced expression of HSP27 in OA-chondrocytes compared to 
chondrocytes isolated from healthy cartilage (33 % reduction, p<0,05-Mann Whitney U-test) 
(Figure 3 and 4). In 5 of the 6 patients analysed, HSP27 shows a higher expression in 
chondrocytes isolated from visually intact compared to visually damaged zones from the same 
knee joint. 
 
 
 
 
 
Figure 3: Expression of HSP27 in human articular chondrocytes isolated from healthy and OA 
cartilage. The protein levels of HSP27 in extracts of chondrocytes isolated from healthy cartilage 
(lanes 1-2 and 7-10) and from visually intact (lanes 3-4 and 11-14) and visually damaged zones (lanes 
5-6 and 15-18) of OA cartilage were determined by Western blot analysis. Equal loading was verified 
using Ponceau S (data not shown). 
 
Further research will be needed to elucidate the true biological role of this differential 
expression in the pathogenesis of OA. However, based on current literature, a significant role 
role may be suspected. In cell lines, HSP27 has been reported as a downstream effector of 
TGF-β  [21], a key growth factor in chondrocyte metabolism [22]. Moreover, it has been 
shown that overexpression of HSP25 (the murine analogue of HSP27) in C1 cell lines, 
interferes with chondrogenic differentiation of this cell line [23].  
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This study serves as a first exploration of the ‘hidden’ proteome of articular chondrocytes, 
resulting in the identification of several low-abundance and membrane proteins expressed by 
the chondrocyte. Therefore, a variety of sample preparation methods based on different 
protein and peptide properties were combined and applied to different samples. Based on 
current and future knowledge of important pathways and differentially abundant protein 
species, the provided database could assist in the rational selection of candidate experimental 
targets. This was demonstrated by the selection of HSP27, a protein closely related to the 
previously described αBcrystallin. Moreover, a more extended view on the chondrocyte’s 
proteome may assist in the development of protein- as well as cDNA-arrays, which cover 
novel identified genes expressed by chondrocytes. 
Furthermore, this report opens up perspectives to introduce a ‘gel-free’ comparative analysis 
between healthy and OA-chondrocytes. Further experiments are essential to select the most 
optimal workflow in terms of reproducibility and proteome coverage, thereby enabling 
differential proteome analyses based on labelling strategies.  
 
 
 
Figure 4: Densitometric analysis of Western 
blots reveals a differential expression 
between the sample groups. Upper panel: 
Results of the densitometric analysis, 
showing the mean expression (± SEM) in 
each group (normalized to NoNo expression 
levels). P-values were calculated using 
Mann-Whitney U-test for the comparison 
between NoNo vs NoOA and NoNo vs 
OAOA. NoOA and OAOA samples were 
compared by Wilcoxon’s paired sample test. 
Black bars: NoNo; white: NoOA; shaded: 
OAOA. Lower panel: Results of the 
densitometric analysis, showing the 
expression levels of HSP27 in chondrocytes 
isolated from visually intact zones (NoOA) 
and visually damaged zones (OAOA) of the 
same knee joint from 6 different patients. 
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Chapter IV: Summary and future perspectives 
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 Osteoarthritis (OA) is the most common form of arthritis. In contrast to what would be 
expected by its name, this disease is generally considered to be a non-inflammatory joint 
disease. The major hallmark of OA is the progressive degeneration of the articular cartilage. 
Chondrocytes play a pivotal role in the normal metabolism of the cartilage matrix [1]. The 
failure to maintain the balance between synthesis and degradation of the extracellular matrix 
by the chondrocyte ultimately results in cartilage degeneration, distinctive for OA. As 
discussed in the introduction, a body of knowledge is available concerning cellular processes 
activated during the disease. In recent years, this knowledge was extended with data from the 
bio-molecular toolbox. However, the data from the proteome-level were unexisting or at least 
very limited.  
 
The primary study was based on the hypothesis that the knowledge of differentially abundant 
proteins between chondrocytes isolated from ‘normal’ and OA-patients, may assist in 
unravelling novel disease processes activated in OA. So, the initial goal of this study was to 
identify differentially abundant proteins, using a 2-DE proteome approach. Such approach 
allows exploring the level of the effectors, namely the proteins. Moreover, it is an unbiased 
technique, thereby allowing the identification of novel targets. This study revealed the 
differential expression of several new players associated with processes known to be involved 
in the pathogenesis of OA, such as apoptosis [2], metabolic activation [3] and oxidative stress 
[4]. During this first study, we mainly focussed on two spots, both identified as vimentin. 
Based on spot patterns and mass spectrometry data, an enhanced N-terminal cleavage in OA-
chondrocytes could be concluded. Given the involvement of the amino-terminal domain in 
intermediate filament assembly [5] and in membrane interactions [6], we investigated whether 
the observed cleavage influenced vimentin organisation. Indeed, a distorted vimentin 
organisation was visualized by immunofluorescence microscopy. The functional implications 
hereof may be of great interest. It is known that vimentin intermediate filaments may be 
involved in the visco-elastic properties of human articular chondrocytes [7]. In addition, 
chemical induced disassembly of the vimentin cytoskeleton, results in the disturbance of the 
normal chondrocyte homeostasis [8]. The importance of the cytoskeleton on 
mechanotransduction events was previously demonstrated [9]. Especially in the case of the 
chondrocyte, the cellular constituent of the weight baring cartilage, these events could be very 
important. The primary cause of the observed vimentin cleavage remains elusive. 
Undoubtedly, the knowledge hereof will assist in the evaluation of the true biological value of 
our findings. Screening of the activity of intracellular proteases, which are known to target 
129
 vimentin, and inhibition of their activity may be a first step in future research. Furthermore, 
full characterization of the primary structure of the different vimentin isoforms may provide 
new insights and assist in further elucidation of the associated pathways. 
 
In the second part of this study, we validated the differential expression of the small heat 
shock protein αBcrystallin and the functional implications thereof. This protein showed a 
gradual decrease in expression from healthy chondrocytes to chondrocytes isolated from 
visually damaged zones of OA-patients. Given the very limited knowledge concerning small 
heat shock proteins in chondrocytes, we further explored this very attractive target. One of the 
major hallmarks of OA chondrocytes is the involvement of pro-inflammatory cytokines in the 
activation of catabolic pathways [10]. Interestingly, the abundance of αBcrystallin showed to 
be IL-1β and TNF-α dependent, presenting this protein as a novel potential mediator of these 
key-cytokines in OA pathogenesis. Moreover these data implicate the potential involvement 
of a cytokine-driven mechanism in the suppression of αBcrystallin expression in OA 
chondrocytes. The observed decreased expression in OA chondrocytes was imitated by a 
siRNA induced suppression of the CRYAB gene expression. The application of high-
efficiency knock-down technologies in chondrocyte research, revealed the association 
between a reduced αBcrystallin expression and the diminished expression of genes that are 
characteristic for the differentiated chondrocyte phenotype. Given the observed variable 
expression during chondrocyte dedifferentiation, this protein may be associated with the 
maintenance of the stable chondrocyte phenotype and its loss during the development of OA.  
The availability of an αBcrystallin knock-out model [11] opens up perspectives to investigate 
the in vivo role of this protein in cartilage biology. The application of OA models (e.g. 
collagenase-induced or surgically induced by anterior cruciate ligament transection [12]) on 
αBcrystallin knock-out and control mice might assist in further evaluation of this interesting 
gene. Moreover, future studies will have to reveal if modulating the CRYAB expression in 
chondrocytes will result in an increased synthesis of functional extracellular matrix 
components. Alternatively, modulating the expression of this gene in chondrocyte precursors 
or fibroblasts generated from expanded chondrocytes may result in the differentiation towards 
a more stable chondrocyte phenotype.  
 
A final chapter describes an exploration of the proteome expressed by human articular 
chondrocytes. Sample prefractionation methods based on different protein and peptide 
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 properties were combined and applied to different samples, resulting in the construction of a 
chondrocyte proteome database. Based on current and future knowledge of important 
pathways and differentially abundant protein species, this database could assist in the rational 
selection of candidate experimental targets. This was demonstrated by the selection of HSP27, 
a protein closely related to the previously described αBcrystallin. Future differential 
expression profiling experiments, whether targeted (e.g. Western blotting) or not (e.g. iTRAQ 
analysis), may aid in the evaluation of other targets (e.g. peroxiredoxins) provided by this 
proteome map. Alternatively, the provided proteome map may assist in the development of 
protein- or cDNA-arrays to evaluate expression levels of novel identified gene expression 
products. The ultimate goal of proteome profiling studies is to identify extremely low 
abundant proteins (e.g. cytokines or cytokine receptors in the particular case of chondrocytes). 
For cartilage samples, the amount of starting material is limited. Therefore, further technical 
improvements based on alternative fractionation methods and/or improvements in MS 
sensitivity are essential to assist in further digging in the chondrocyte proteome. 
A major opportunity enabled by analyzing the protein level is the ability to discover post-
translational modifications. In recent years it has become clear that PTMs are involved in the 
pathogenesis of several diseases (e.g. citrullination in RA). Therefore, specific profiling of 
PTMs such as phosphorylation (e.g. by selective enrichment of phosphoproteins) or protein 
cleavage (e.g. by N-terminal modification) may disclose novel disease-associated pathways 
and processes.  
  
The initial 2-DE approach was the central feature of this study. The knowledge of the 
differential expression/abundance of a given protein or a given isoform on itself is interesting, 
but has limited biological value. Especially when the number of samples in the analyzed 
groups is limited, due to limited availability of patient samples, further validation is critical. 
Therefore, proteome analyses should be considered as discovery tools. The combination of 
different complementary proteome approaches, constitute a very important tool to kick-off the 
discovery process. Integration of these discovery tools with independent, multi-disciplinary 
approaches enabled us to present ‘novel’ proteins which may lead to new insights in the 
pathogenesis of OA. Hopefully, future research based on in vitro and in vivo data will 
elucidate the true biological role of these proteins. 
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 Artrose (OA) is de meest voorkomende gewrichtsaandoening in de westerse wereld. Deze 
aandoening wordt algemeen als een niet-inflammatoire pathologie beschouwd. OA is door 
een progressieve afbraak van het gewrichtskraakbeen gekenmerkt. De kraakbeencellen of 
chondrocyten, die autonoom instaan voor de synthese van de kraakbeenmatrix, spelen een 
sleutelrol in het metabolisme van het kraakbeen [1]. Algemeen wordt aangenomen dat een 
verstoring van het evenwicht tussen katabole en anabole processen leiden tot de afbraak van 
het kraakbeen, geassocieerd met OA. Er zijn reeds heel wat processen beschreven die in de 
pathogenese van OA betrokken zijn. De jongste jaren werd deze kennis door de snelle 
vooruitgang in de moleculaire biologie verder uitgebreid. Desalniettemin waren bij het begin 
van dit werk nagenoeg geen data beschikbaar op basis van proteoom-analyses in dit domein.  
 
De werkhypothese, die de basis vormde voor deze studie, bestond erin dat de kennis van 
eiwitten die een verschillende abundantie vertonen in kraakbeencellen geïsoleerd uit normaal 
en artrotisch kraakbeen, nieuwe inzichten in de pathogenese van OA konden verschaffen. Het 
initiële doel van deze studie was dan ook om die eiwitten (of isovormen van eiwitten) te 
identificeren aan de hand van een differentiële proteoom-analyse op basis van 2-D gel 
elektroforese. Deze techniek biedt het voordeel dat het onderzoek wordt verricht op het 
niveau van de functionele componenten in een cel, namelijk de eiwitten. Bovendien hoeft men 
op voorhand niet te weten welke eiwitten onderzocht dienen te worden, wat dan weer toelaat 
om vernieuwende processen te ontdekken. Deze differentiële proteoom-analyse leidde tot de 
identificatie van nieuwe spelers in processen die algemeen gekend zijn in de pathogenese van 
artrose, zoals apoptose [2], metabole activatie [3] en oxidatieve stress [4]. Het verdere 
onderzoek in deze studie was hoofdzakelijk gericht op de validatie van twee differentiële 
spots, beide geïdentificeerd als vimentine. Een combinatie van massaspectrometrie- en 
Western blot-data toonde een verhoogde afbraak van de vimentine eiwitsequentie ter hoogte 
van het amino-terminaal gedeelte in OA-kraakbeencellen aan. Het is gekend dat dit amino-
terminaal stuk van de eiwitsequentie betrokken is in de organisatie van het vimentine 
cytoskelet [5] en in de interactie van het eiwit met de celmembraan [6]. Immunofluorescentie-
experimenten toonden inderdaad aan dat in OA-chondrocyten de vimentine-organisatie 
verstoord was. Deze bevinding kan mogelijks belangrijke functionele implicaties hebben op 
de cel. Men heeft namelijk beschreven dat het vimentine cytoskelet bijdraagt tot de visco-
elastische eigenschappen van kraakbeencellen [7]. Bovendien werd aangetoond dat chemisch 
geïnduceerde afbraak van het vimentine cytoskelet resulteert in een verstoring van de 
metabole homeostase in kraakbeencellen [8]. Er werd verder ook aangetoond dat het 
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 vimentine cytoskelet betrokken is in mechanotransductie-pathways [9]. Verder onderzoek zal 
moeten uitwijzen welke processen verantwoordelijk zijn voor de geobserveerde vimentine-
afbraak tijdens de ontwikkeling van artrose. De kennis van deze processen zal ongetwijfeld 
verder bijdragen tot de evaluatie van het biologische belang van onze resultaten. 
 
In het tweede gedeelte werd de geobserveerde differentiële expressie van αBcrystallin verder 
gevalideerd. Bovendien werd nagegaan wat de mogelijke functionele implicaties zijn van een 
gewijzigde expressie van dit gen. Vóór deze studie was weinig gekend over de functie en het 
gedrag van “small heat-shock proteins” in chondrocyten. Western blots bevestigden de lagere 
expressie van αBcrystallin in OA-stalen in vergelijking met chondrocyten geïsoleerd uit 
gezond kraakbeen. De betrokkenheid van pro-inflammatoire cytokines in de activatie van 
katabole processen is algemeen gekend in chondrocyten [10]. Tijdens onze studie 
observeerden we dan ook dat stimulatie van chondrocyten met pro-inflammatoire cytokines 
zoals IL-1β en TNF-α gepaard gaat met een lagere expressie van αBcrystallin. Dit kan erop 
wijzen dat dit eiwit een mogelijke mediator is van het effect van deze cytokines in 
chondrocyten. Bovendien wijst dit er ook op dat de lagere expressie van αBcrystallin in OA-
chondrocyten wellicht het gevolg is van een cytokine-gedreven mechanisme. Om diepere 
inzichten te verwerven in de mogelijke functionele gevolgen van een gedaalde αBcrystallin-
expressie werd de expressie van het CRYAB-gen onderdrukt door middel van “short-
interfering RNA”. Deze gedaalde expressie bleek geassocieerd te zijn met een lagere 
expressie van genen die kenmerkend zijn voor een gedifferentieerde chondrocyt, namelijk 
BMP-2, collageen type II en aggrecan. Verder werd waargenomen dat dedifferentiatie van 
chondrocyten gepaard gaat met een initiële daling van de CRYAB-expressie, wat er op wijst 
dat dit gen bij het behoud van een stabiel fenotype van chondrocyten betrokken kan zijn.  
De beschikbaarheid van een CRYAB “knock-out” model [11] opent nieuwe perspectieven om 
de rol van dit gen in vivo te bestuderen. De toepassing van OA-diermodellen (bv. 
collagenase-geïnduceerd of operatief geïnduceerd [12]) op deze knock-out muizen zal 
mogelijks een dieper inzicht geven in de rol van dit gen in de fysiologie van kraakbeencellen. 
Bovendien zullen toekomstige studies moeten aantonen of het mogelijk is om de chondrogene 
capaciteit van chondrocyten te beïnvloeden door de expressie van αBcrystallin te moduleren. 
Een andere mogelijkheid kan er in bestaan om de expressie van dit gen te moduleren in 
chondrocyt-precursoren of fibroblasten (gegenereerd uitgaande van chondrocyten tijdens 
expansieculturen) teneinde deze cellen te laten differentiëren naar chondrocyten.  
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In een laatste hoofdstuk werd het proteoom van chondrocyten verder onderzocht. Staal-
fractionering gebeurde op basis van verschillende fysicochemische eigenschappen van de 
eiwitten en peptiden. Dit resulteerde uiteindelijk in een databank van eiwitten die in 
chondrocyten tot expressie komen. Het doel van deze databank bestaat erin om, op basis van 
gekende processen en gekende differentiële eiwitten, op een rationele manier nieuwe, 
mogelijke interessante, eiwitten te onderzoeken. Uit de databank bleek dat heat shock protein 
27 (HSP27) tot expressie komt in chondrocyten. Dit eiwit is zowel structureel als functioneel 
zeer sterk verwant met αBcrystallin. De expressie van HSP27 werd dan ook verder 
onderzocht en vergeleken tussen normale en OA-chondrocyten. Verder differentieel 
onderzoek op basis van al dan niet gerichte kwantificatie (vb Western blotting of iTRAQ) zal 
ons in staat stellen om andere interessante eiwitten te evalueren. Bovendien kan deze 
databank een hulp zijn bij het ontwikkelen van eiwit- of cDNA-arrays om de expressieniveaus 
te evalueren van eiwitten die nog niet gekend waren in chondrocyten.  
Het ultieme doel in dergelijke studies, die erop gericht zijn om het proteoom zo volledig 
mogelijk te beschrijven, bestaat erin om zeer laag abundante (vb cytokines of hun receptoren) 
eiwitten te identificeren. In het geval van kraakbeen is de hoeveelheid te isoleren eiwit 
beperkt. Verdere vooruitgang zowel op LC-MS vlak als op het vlak van staalvoorbereiding 
zal ons hopelijk in staat stellen om deze zeer laag abundante eiwitten te identificeren. 
Eén van de belangrijkste voordelen van een proteoom-analyse bestaat in de mogelijkheid om 
post-translationele modificaties te identificeren. Het is algemeen gekend dat dergelijke 
modificaties betrokken zijn in de pathogenese van heel wat aandoeningen (vb. citrullinatie in 
RA). Het beschrijven van gemodificeerde isovormen, zoals fosforylatie of proteolytische 
afbraak van eiwitten, zal ongetwijfeld leiden tot de ontdekking van nieuwe ziekte-
geassocieerde processen en mogelijks specifiekere biomerkers.  
 
De initiële differentiële proteoom-analyse vormde de basis voor dit werk. De kennis van 
differentieel abundante eiwitten of eiwit-isovormen is interessant, maar heeft slechts een 
beperkte biologische waarde. Zeker in het geval van klinische stalen, die beperkt zijn in 
aantal, is verdere validatie absoluut noodzakelijk. Het is dan ook steeds duidelijker dat 
proteoom-analyses zeer waardevol zijn in het ontdekken van mogelijks interessante 
processen. De combinatie van complementaire proteoom-benaderingen kan deze informatie 
verder aanvullen. De integratie van de proteomics-discipline met andere technieken die 
complementaire informatie verschaffen hebben ons in staat gesteld om “vernieuwende” 
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 eiwitten/genen als mogelijke mediatoren in de pathogenese van OA naar voor te schuiven. 
Verder onderzoek, gebaseerd op zowel in vitro als in vivo experimenten, zal ons hopelijk in 
staat stellen om de rol van deze eiwitten in OA verder te evalueren. 
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Dank U! 
 
Deze doctoraatsthesis is uiteraard tot stand gekomen dankzij de hulp van vele mensen. In de 
eerste plaats mijn (co-)promotoren Prof. Deforce en Prof. Elewaut: Jullie hebben me 
toegelaten om met de nodige zelfstandigheid dit project uit te werken en tegelijkertijd met een 
gezonde portie kritiek het werk bijgestuurd. Wat mij betreft mag deze samenwerking in elk 
geval nog een tijdje blijven duren. Daarnaast (en misschien nog veel belangrijker) hebben 
jullie er voor gezorgd dat er steeds voldoende financiële middelen om de toestellen en 
reagentia te voorzien die nodig waren. In dit opzicht bedank ik ook het FWO-Vlaanderen, die 
mij de voorbije jaren van de nodige financiële middelen heeft voorzien. Verder wens ik ook 
nog Prof. Verbruggen en Dr. Verdonk te bedanken: jullie hebben mij kennis laten maken met 
de kraakbeencellen in de praktijk. In het bijzonder bedank ik Dr. Verdonk en Dr. Almqvist 
voor de geregelde “levering” van de noodzakelijke stalen.  
 
Een speciaal woordje van dank ook voor mijn collega’s en mijn ex-collega’s. In de eerste 
plaats de “(ex-)bewoners” van het 2e verdiep: Ben, Ivan, Aline, Kelly, Ann-Sophie, Maarten, 
Jip, Mado, Katleen en Cynthia. De sfeer, maar ook de gewone ‘goeiemorgen’, de laatste 
roddelkes, het koffietransport naar boven, de discussies (variërende van de buffer-keuze voor 
de LC tot de selectie van het beste bier) en zo veel meer heeft me de voorbije jaren zeer veel 
plezier gedaan. De discussies over de organisatie/opkuis (nu ja, veel ruimte (letterlijk, dan) 
om te organiseren was er misschien niet altijd…) liepen soms hoog op, maar telkens kon de 
vrijdag-avond-duvel (gekoeld à la façon “2e verdiep”) de rust doen terugkeren. In elk geval: 
mochten jullie ooit vinden dat jullie bureau er belachelijk leeg uit ziet, ik zal met plezier eens 
langskomen… Filip, jij hebt wel nooit het 2e verdiep bevolkt, maar voor jou geldt zeker 
hetzelfde als hierboven. 
“Sofie van de massa”: super-veel bedankt voor de hulp de voorbije jaren. Jouw werk 
apprecieer ik ten zeerste. De finesse en vooral het geduld waarmee je een naaldje kan 
positioneren, de lekken kan “dichten”,… is ongeëvenaard binnen het lab. We hebben veel 
moeten uittesten en veel gesukkeld, maar jouw hulp heeft mij veel tijd bespaard.  
Uiteraard ook de mensen van “den DNA”: jullie hulp zat in kleine dingen, maar daarom niet 
minder belangrijk. Enne niet te vergeten, Astrid en Nadine: de bestellingen, faxen, 
administratie en zo veel meer, bedankt hiervoor.  
Daarnaast zijn er nog een reeks mensen die af en toe of tijdelijk in ons labo langskwamen, 
zoals de thesisstudenten, de MRB-people,… (wat dan op zich weer een gelegenheid kon zijn 
voor één of meerdere gezamenlijke etentjes, MRB-BBQ, feestjes…), ook jullie bedankt voor 
de voorbije jaren.  
 
Zonder ontspanning, ook geen inspanning, dus naast de bovenvermelde mensen zijn er nog 
heel wat familie en vrienden die een indirecte bijdrage hebben geleverd aan het welslagen van 
dit werk, dus ook jullie bedankt. In het bijzonder nog een zeer speciaal woordje van dank voor 
“ma en pa”. Zonder jullie was ik hier nooit geraakt, dus een zeer welgemeende merci! Bieke, 
bedankt voor de taal-technische aanpassingen aan de Nederlandstalige tekst en voor zoveel 
meer… Het is moeilijk om in een dankwoord niet in clichés te spreken, en waarom moeilijk 
doen als gemakkelijk evenveel zegt: Last but not least, Wennie, bedankt voor zoveel dingen 
de afgelopen jaren! 
 
 
 
 
 
 143
